A Study on the Association of Mean Platelet Volume with Ischaemic Stroke and Its Correlation with Stroke Subtypes by Bhavana, V
A STUDY ON THE ASSOCIATION OF MEAN PLATELET 
VOLUME WITH ISCHAEMIC STROKE AND ITS 
CORRELATION WITH STROKE SUBTYPES 
 
 
 
 
 
 
 
 
Dissertation submitted in 
Partial fulfilment of the regulations required for the award of 
M.D. GENERAL MEDICINE 
BRANCH I 
 
 
 
 
 
 
 
 
THE TAMILNADU 
DR. M.G.R. MEDICAL UNIVERSITY 
CHENNAI 
APRIL 2015 
 
CERTIFICATE BY THE GUIDE 
 
This is to certify that this dissertation in “A STUDY ON THE 
ASSOCIATION OF MEAN PLATELET VOLUME WITH ISCHAEMIC 
STROKE AND ITS CORRELATION WITH STROKE SUBTYPES”is a 
bonafide research work done by Dr. V.Bhavana, under my guidance 
during the academic year 2012- 2015. 
 
This has been submitted in partial fulfilment of the award of 
M.D.Degree in General Medicine (Branch-I) by the Tamil Nadu 
Dr.M.G.R. Medical University, Chennai- 600 032.  
 
 
 
Date:      PROFESSOR and GUIDE 
Department of General Medicine  
Coimbatore Medical College. 
 
 
 
Date:                                PROFESSOR and HEAD OF DEPT.  
Department of General Medicine  
Coimbatore Medical College. 
 
 
Date:                    THE DEAN  
Coimbatore Medical College, Coimbatore 
  
   
   
  
 DECLARATION 
 
          I solemnly declare that this dissertation entitled “A STUDY ON THE 
ASSOCIATION OF MEAN PLATELET VOLUME WITH  ISCHAEMIC 
STROKE AND ITS CORRELATION WITH STROKE SUBTYPES”  is a 
bonafide and genuine research work carried out by me at Coimbatore Medical 
College and Hospital during the academic year 2012-2015 under the guidance 
and supervision of  Dr. S. Chandrasekaran,  M.D., Professor, Department of 
Medicine, Coimbatore Medical College Hospital, Coimbatore. 
 
This dissertation is submitted to the Tamil Nadu Dr.M.G.R. 
Medical University, towards the partial fulfilment of requirement for 
the award of M.D.Degree in General Medicine (Branch-I). 
 
 
Place:  
Date:                                                                  Dr. V.Bhavana 
  
ACKNOWLEDGEMENT 
With great reverence, first of all, I would like to express my deep sense of 
gratitude to my guide and teacher, Prof. Dr S. Chandrasekaran M.D., 
Professor of Medicine, Coimbatore Medical College, Coimbatore. He has been 
more than a guide, a good mentor and a source of constant inspiration  
throughout my course. I also thank him for his able guidance, suggestions and 
supervision throughout the making of this dissertation. 
 
I would consider it my privilege to extend my respect and gratitude to 
Prof. Dr. N. Kumar Natarajan  M.D., Head of the Department of Medicine, 
Coimbatore Medical College, Coimbatore, for all the encouragement and 
guidance. I also express my sincere gratitude to Dr. N.Sundar MD, for his 
guidance and support. 
 
I also sincerely express my thanks to my Assistant Professors,                   
Dr. S.Avudaiappan M.D., Dr.A.Nilavan M.D., Dr.K.Sivakumar MD,           
Dr.B. Vetriveeran MD in the Department of Medicine, Coimbatore Medical 
College, Coimbatore, for all their effort and guidance throughout the course, for 
which words fall short of. I am indeed indebted to them. 
 
 
 
 
 
 
I would also like to express my thanks to The DEAN,                               
Dr. S. Revwathy M.D., DNB OG, for her able guidance and encouragement 
throughout. I also am thankful to the administration and other allied 
departments of the Coimbatore Medical College for their support in helping me 
carrying out this study. 
 
I express my heartfelt sincere thanks to all my fellow postgraduates, for 
their unconditional support and guidance, and for just being there. No words can 
express the support extended by my family in all these years; thank you. 
 
My biggest gratitude will always be towards my patients, without whose 
cooperation this study would have been incomplete. I thank the Almighty for his 
abundant blessings.    
 
 
Date:  
Place:                                      Dr.V. Bhavana 
 
 
 
 
 
 
  
  
 
 
TABLE OF CONTENTS 
 
 
S.NO TITLE PAGE NO 
1 INTRODUCTION 1 
2 AIMS AND OBJECTIVES 4 
3 REVIEW OF LITERATURE 5 
4 MATERIALS AND METHODS 48 
5 OBSERVATIONS AND RESULTS 71 
6 DISCUSSION 87 
7 SUMMARY 96 
8 CONCLUSION 100 
9 BIBLIOGRAPHY 101 
10 ANNEXURES  
 PROFORMA 109 
 CONSENT FORM 114 
 MASTER CHART 118 
 KEY TO MASTER CHART 129 
 
 
 
 
 
  
 LIST OF TABLES 
 
SL 
NO 
TITLE OF TABLE PAGE NO 
1 Risk factors of stroke 20 
2 Structural zones of platelet 28 
3 Contents of the different granules of platelets 30 
4 Stroke log and reasons for exclusion 71 
5 Age distribution 73 
6 Gender distribution 75 
7 Risk factor profile 76 
8 Clinical profile 77 
9 The  Oxfordshire community stroke project classification 
of  stroke 
79 
10 Stroke clinical severity score 80 
11 Comparison of platelet counts in cases and controls 81 
12 Comparison of MPV in cases and controls 82 
13 Stroke subtypes and MPV 84 
14 Correlation between platelet count and stroke subtype 85 
15 Correlation between stroke severity and MPV 86 
16 Comparison of demographic data of current study with 
western literature 
88 
17 Comparison of risk factor profile of current study with 
western literature 
89 
18 Comparison of drug history of patients in current study 
with western literature 
90 
19 Comparison of platelet parameters of current study with 
western literature 
91 
 LIST OF CHARTS 
 
 
SL NO TITLE OF THE CHART PAGE 
NO 
1 Stroke log and reasons for exclusion 72 
2 Age distribution 74 
3 Gender distribution 75 
4 Risk factor profile 77 
5 Clinical profile 78 
6 Stroke subtypes 80 
7 Stroke clinical severity score 81 
8 Comparison of platelet counts in cases and controls 82 
9 Comparison of MPV in cases and controls 83 
10 Stroke subtypes and MPV(EDTA) 84 
11 Stroke subtypes and MPV(citrate) 85 
12 Correlation between platelet count and stroke subtype 86 
 
 
 
LIST OF FIGURES 
 
SL NO TITLE OF FIGURES 
 
PAGE NO 
1 Anterior circulation 7 
2 Arterial supply to brain 10 
3 Circle of Willis 11 
4 Cortical vascular territories 12 
5 Anatomy of proplatelets 23 
6 Microscopic appearance of platelets on Leishman 
stained smear 
24 
7 Subcellular organization of resting platelet 27 
8 Structural zones of platelet 28 
9 Formation of a haemostatic platelet plug 34 
10 Platelet formation 40 
11 Principle behind automated haematology analyser 53 
 
 
 
 
 
 
 
ABBREVIATIONS 
 
ACA - anterior communicating artery 
ACE- angiotensin converting enzyme 
ADP-adenosine diphosphate 
ATP- adenosine triphosphate 
ATP-3 –adult treatment panel -3 
b-TG- b-thromboglobulin 
CCA- common carotid artery 
CT-computed tomography 
DNA- deoxy ribonucleic acid 
ECA-external carotid artery 
EDTA-ethylene diamine tetra acetic acid 
fL-femtolitre 
ICA- internal carotid artery 
LACS- lacunar syndrome 
MCA-middle cerebral artery 
MK- megakaryocyte 
MPHA- megakaryocyte platelet haemostatic axis 
MPV- mean platelet volume 
NIHSS- national institutes of health stroke scale 
OCSP- Oxfordshire community stroke project 
PACS- partial anterior circulation syndrome 
PCA- posterior cerebral artery 
PCT- platelet count 
PDW- platelet distribution width 
PoCA- posterior communicating artery 
POCS- posterior circulation syndrome 
PROGRESS- perindopril protection against recurrent stroke study 
SCCS- surface connected canalicular system 
SOP- standard operating procedure 
TACS- total anterior circulation syndrome 
TIA- transient ischaemic attack 
vWF- von Willebrand factor 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
ABSTRACT 
 
Background and Objectives 
 
          Stroke is one of the most common neurological disorders. Ischaemic 
stroke occurs due to thrombus occluding a stenosed atherosclerotic blood vessel. 
Platelets have a crucial role in the pathophysiology of atherothrombosis. 
Ischaemic Cerebrovascular disease (ischaemic stroke) is one of the leading 
public health problem. From the late 1990s, there has been an increase in 
survival after stroke. So it has become a very common cause of suffering and 
one of the leading cause of long-term disability. 
 
            Large platelets are more reactive, produce more prothrombotic factors 
and aggregate more easily. So the detection of large platelets in patients with 
ischaemic stroke support the idea that platelet volume influences thrombotic 
large vessel occlusion. There are very few documented studies in India 
comparing the association of mean platelet volume with ischaemic stroke. So I 
intend to make an attempt to find out the association between mean platelet 
volume and ischaemic stroke. Objectives of the study was to find out whether a 
significant association exist between the occurrence of ischaemic stroke and 
mean platelet volume as well as to find out whether a significant association 
exist between stroke subtype and mean platelet volume. 
 
 
Methods: 
The study was a prospective case control study  conducted at Coimbatore 
Medical College and data was collected over a period of six months from  
December 2013 to may 2014.  The study was conducted  amongst100 patients 
diagnosed with acute ischemic stroke and who presented to the hospital within 
48 hours of onset of symptoms. Hundred controls were also selected. Controls 
were matched for age, sex,known  risk factors including hypertension, diabetes, 
dyslipidemia, smoking,and alcoholism.  
 
Each case was assessed and severity of stroke assessed using the  NIHSS. Blood 
sample was collected for measuring mean platelet volume, peripheral smear and 
platelet count. 
Results 
 The main parameter studied was MPV. MPV has got a statistically significant 
correlation with ischaemic stroke with a p value less than 0.001. The average 
MPV in cases was 8.35±0.98 (EDTA) and 7.93±0.99 (citrate). The average 
MPV in controls being 7.81±0.79 (EDTA) and 7.30±0.74 (citrate). Therefore, 
the study shows  an elevated MPV  in the acute phase of  ischaemic stroke. This 
study did not find a statistically significant correlation between clinical severity 
of stroke and mean platelet volume. This study also showed no statistically 
significant correlation between mean platelet volume and stroke subtypes. 
Key words: Ischaemic stroke; stroke outcome;mean platelet volume; platelet 
 
INTRODUCTION 
 
 
          Stroke is one of the most common neurological disorders. Ischaemic 
stroke occurs due to thrombus occluding a stenosed atherosclerotic blood vessel. 
Platelets have a crucial role in the pathophysiology of atherothrombosis. 
Ischaemic Cerebrovascular disease (ischaemic stroke) is one of the leading 
public health problem. Every 53 seconds, one individual in the United States 
gets a stroke. Every year, around 750,000 Americans have a first or recurrent 
ischaemic stroke. Stroke incidence is much more common in other countries. 
Rates are especially high in Asia and Eastern Europe. Occurrence  rates of 
stroke differ considerably among  different regions; for example, the incidence 
of stroke is decreasing in Western Europe and North America while it is on the 
rise in Eastern Europe. Definitive data about stroke from many developing and 
underdeveloped countries are unavailable.But  stroke is likely to be a major 
health problem in these nations. Increase in life expectancy of individuals in 
developing countries has made stroke an important worldwide problem.
65,66 
In 
India, community surveys  show a  prevalence rate for hemiplegia in the range 
of 200 per 1,00,000 persons. Stroke accounts for nearly 1.5 percent of all urban 
hospital admission, 4.5% of all medical and around 20% of all neurological 
cases.
67
 Stroke is next only to heart disease as a leading cause of death 
worldwide.  
          From the late 1990s, there has been an increase in survival after stroke. So 
it has become a very common cause of suffering and one of the leading cause of 
long-term disability. A stroke often precludes patients’ capacities to return to 
work or to regain their role in family. Thus stroke is a family illness. Disability 
may require a spouse or other relative to assume a new role or become a full-
time care giver. Stroke is second only to dementia as a neurological disorder 
leading to long term institutionalized care. Recurrent stroke produces dementia, 
and its effects exacerbate cognitive impairments from degenerative dementias, 
such as Alzheimer’s disease.
65 
 
         Due to the high incidence of stroke and the high costs expended for each 
individual patient, it accounts for a sizeable amount of the health care costs. 
Thus, stroke and its sequelae are important issues for health care planners. 
Because the costs of treatment and the economic consequences of lost 
productivity are so great, prevention of stroke will be a very cost effective 
strategy.
65 
                      
Ischaemic cerebrovascular disease encompasses a broad spectrum of 
clinical events based on the type and duration of the neurological symptoms, the 
area of brain affected, the involved artery, and the presumed cause. This 
classification is important in establishing a patient’s prognosis and making 
decisions about evaluation and treatment.
 
 
          Although the term cerebrovascular accident (CVA) is used widely by 
physicians and other health care professionals, it is an appalling pseudoscientific 
characterization of stroke that substitutes labeling for understanding. The term 
should be abandoned because many strokes are not accidents, but preventable 
catastrophes. 
            A stroke is rapidly developing clinical symptoms and / or signs of focal, 
and at times global  loss of  brain function with symptoms lasting more than 24 
hrs or leading to death, with no apparent cause other than that of vascular 
origin.
68
 
          Thus, the definition of stroke is clinical and laboratory studies including 
brain imaging are used to support the diagnosis. The clinical manifestations of 
stroke are highly variable because of the complex anatomy of the brain and its 
vasculature.
69
 
         Large platelets are more reactive, produce more prothrombotic factors and 
aggregate more easily. So the detection of large platelets in patients with 
ischaemic stroke support the idea that platelet volume influences thrombotic 
large vessel occlusion. There are very few documented studies in India 
comparing the association of mean platelet volume with ischaemic stroke. So I 
intend to make an attempt to find out the association between mean platelet 
volume and ischaemic stroke. 
 
 OBJECTIVES 
 
 
1. 1.To find out whether a significant association exist between the 
occurrence of ischaemic stroke and mean platelet volume. 
 
2. To find out whether a significant association exist between stroke subtype 
and mean platelet volume. 
 
3. To find out the association between stroke severity and mean platelet 
volume. 
 
 
  
3.1 STROKE 
 
3.1.1 HISTORY 
 
          The father of medicine, Hippocrates, described stroke as a sudde onset 
paralysis around 2400 years ago. Cerebrovascular disease is historically more 
ancient than heart disease. In ancient era, stroke was known as apoplexy 
15
.Apoplexy was a recognized clinical syndrome and cause of death before the 
time of Hippocrates. Johan Jakob Weefer a Swiss Physician (1620-1695) seems 
to have been the first to suggest that apoplexy was caused by blood vessels of 
the brain.
15
Discrimination between cerebral hemorrhage and cerebral infarction 
was made by Morgagni (1682-1771) of Padua. William Sen House Kirles 
(1852) was the first to give description of cerebral embolism. Panam first 
proposed that debris from atherosclerotic plaques can cause emboli. This view 
was accepted and the yellow softening, described by Ring Fleisch in 1873 was 
agreed to be due to preceeding obstruction of the supplying artery, usually by a 
clot and cerebral thrombosis was established as an important cause of stroke.  
          Loman and Myerson in 1936 introduced coronary angiography. Godfrey 
Hounsefield in 1972 invented CT scan and has revolutionized the diagnosis and 
treatment of stroke.
70
 
 
 
 
3.1.2 EPIDEMIOLOGY 
3.1.2a: INCIDENCE AND PREVALENCE 
          Occurrence of cerebrovascular disease  increases  with age.They are 
amongst  major causes of disability.As the elderly population increases ,there 
will be an increase in the number of strokes.It is expected that there would be a 
doubling of deaths in the United States by the year 2030.
10
 
 
3.1.2b:INDIAN SCENARIO 
 
          The stroke prevalence in India was found to be 203 per 100,000 in above 
20 years of age population .This shows that there would be around one million 
cases in India . Ratio between males and females is around 1.7.The prevalence 
of stroke in population below 40 years is around 12%.It is estimated that around 
1.2% of total deaths in India is due to strokes.13 
 
3.1.3 ANATOMY 
BLOOD SUPPLY TO THE BRAIN 
 
          The brain constitutes  2 percent of total body weight. But it  receives 
almost 20 percent of the cardiac output at rest. It also consumes about 20 
percent of total inspired oxygen. The rich blood supply is by the 2 internal 
carotid and 2 vertebral arteries. They anastomose at base of  brain forming the 
circle of Willis. Carotid arteries supply the anterior parts of the brain. 
Vertebrobasilar arterial system supplies the posterior  portions of the brain.
69
 
          Internal carotid artery (ICA) :begins as  carotid sinus at the bifurcation 
of common carotid artery (CCA) ,at the level of  thyroid cartilage. It courses up 
the neck, without giving any branches, to the base of  skull. It course through 
the foramen lacerum to enter the carotid canal of  petrous bone. It then runs 
through the cavernous sinus in an S-shaped curve (the carotid siphon), pierces 
the dura, and exists just medial to the anterior clinoid process.It  then bifurcates 
into anterior cerebral  and  large middle cerebral artery.
69 
 
Fig.1 : Anterior circulation 
           External carotid artery (ECA)  :starts at the CCA bifurcation. Branches 
supply the jaw, face, scalp, neck, as well as meninges (superficial temporal, 
facial, occipital arteries, etc).
69
 
          ICA gives off its first major branch, the ophthalmic artery and arises in 
the cavernous sinus. It courses through optic foramen to supply eye and other 
parts in the orbit.
69 
 
         The posterior communicating artery (PoCA) is the next to arise from 
the ICA. It courses backwards to join  first part of the posterior cerebral artery, 
thereby contributing to the circle of Willis. Small  branches also supply adjacent 
optic chiasm, hypothalamus, and midbrain.
69 
 
          The anterior choroidal artery arises from the last section of ICA, just 
beyond the PoCA origin.It  supplies the optic tract, internal capsule, basal 
ganglia, the medial part of  temporal lobe, thalamus, lateral geniculate body, 
proximal optic radiation, and midbrain. It may arise from proximal middle 
cerebral artery or PoCA. Minor twiglets from distal ICA contribute blood to the 
pituitary gland, optic chiasm, and the meninges.
69 
 
          Anterior cerebral artery (ACA): enter the interhemispheric fissure, 
anastomoses with its counterpart on the opposite side through the anterior 
communicating artery (ACoA), curves up around genu of the corpus callosum, 
and supplies anterior and medial parts of cerebral hemisphere. Few small 
branches supply parts of the optic nerve ,optic chiasm, hypothalamus, anterior 
basal ganglia, and internal capsule.
69 
 
          Middle cerebral artery (MCA): enter Sylvian fissure , gives off 2-4 
branches which supply lateral parts of cerebral hemisphere. Main trunk gives 
off  medial and lateral groups of tiny lenticulostriate arteries and arterioles, 
which penetrate  base of the brain and supply  basal ganglia and internal 
capsule. A few of these small penetrating vessels extend up to the white matter 
of corona radiata.
69 
 
           Vertebral artery: arises from  proximal part of subcalvian artery .It 
ascends through  transverse foramina of  sixth to second cervical vertebrae, 
giving off many small muscular branches during its course. It then courses 
posteriorly around articular process of  atlas vertebra  to enter skull through  
foramen magnum. It joins the opposite vertebral artery on ventral surface of 
brainstem at pontomedullary junction to form basilar artery. Branches to the 
meninges are given off at the foramen magnum. The vertebral artery gives off 
the anterior and posterior spinal arteries,  posterior inferior cerebellar artery 
(which supply inferior vermis and posterior as well as inferior surfaces of  
cerebellar hemispheres, and brainstem), and small penetrating arteries tosupply 
medulla.
69
 
           Basilar artery: ascends ventral to the pons till the pontomidbrain 
junction in the interpeduncular cistern. Here it divides into two posterior 
cerebral arteries. Several  small branches penetrate the brainstem and 
thecerebellum. The basilar artery gives off anterior inferior cerebrellar artery (to 
cerebellum, brainstem, inner ear) and  superior cerebellar artery (to brainstem, 
superior half of cerebellar hemisphere, vermis, and the dentate nucleus).
69 
 
Fig:2 Arterial  supply to brain 
  
           Posterior cerebral artery (PCA) :encircles midbrain close to 
oculomotor nerve at the level of the tentorium .It supplies inferior part of  
temporal lobe, and the occipital lobe. Several  perforating arteries arise from 
proximal portion of PCA to supply the midbrain, thalamus, hypothalamus, and 
the geniculate bodies.  
 
In 15 percent people, the PCA is a direct continuation of the PoCA. In this 
situation, its main blood supply comes from the ICA rather than basilar artery.
69
 
 
 
Fig:3 Circle of Willis 
 
Fig4:Cortical vascular territories 
 
 
3.1.4 PATHOPHYSIOLOGY 
 
          A fall in cerebral blood flow to almost nil causes death of brain tissue 
within four to ten minutes. A rate of blood flow less than 16 ml/100g tissue per 
minute cause infarction of brain tissue in about one hour .A flow rate less than 
20ml per 100g of brain  tissue per minute cause ischaemia,but no infarction, 
unless persistent for hours to days.  
          TIA occurs if blood flow is reestablished before significant cell death. 
The tissue which surround the core area of infarction is ischaemic but this area 
is reversibly dysfunctional .This area  is called the ischaemic penumbra. The 
ischaemic penumbra undergo infarctionif there is no change in blood flow. 
Revascularization  procedures are based on this and they aim at preserving 
ischaemic penumbra.
10
 
          There are two different pathways for the occurrence of cerebral 
infarction.First is the necrotic pathway, in which cytoskeleton within the cells 
breakdown rapidly due to energy failure .Second is the apoptotic pathway in 
which cells are programmed to die. 
          Ischaemia produces glucose deficiency in neurons. This result in necrosis 
leading to reduced production of ATP by mitochondria.ATP deficiency result in 
malfunctioning of membrane ion pumps, which in turn lead to neuronal 
depolarization. Hence, the intracellular calcium rises as well as there is release 
of glutamate from the synaptic terminals. Excess of extracellular glutamic acid 
in turn activates postsynaptic glutamate receptors .Receptor activation further 
leads to an increase in the neuronal calcium influx. All these mechanisms lead 
to neurotoxicity. 
          Destruction of membrane lipids and mitochondrial dysfunction favour the 
formation of free radicals. Free radicals induce catalytic damage of membranes.  
Ischaemic penumbra, having lesser degree of ischaemia  ,favours apoptotic cell  
death after few days to weeks .
10 
 
 
 
 
3.1.5  ETIOLOGY 
                                          (A)COMMON CAUSES 
 
    (a)Thrombosis    
 Lacunar stroke 
 
 Thrombosis of large vessels. 
 
 Severe dehydration 
 
     (b)Embolic Occlusion 
 Artery to artery    
         
       Aortic arch 
 
       Carotid bifurcation 
 
                                                               Dissection of artery 
 
 Cardioembolism 
          
         Intra mural thrombus 
            
          Atrial fibrillation 
 
          Myocardial infarction 
 
          Dilated cardiomyopathy 
 
          Valvular lesions 
 
          Infective endocarditis 
           
           Mechanical cardiac valves 
 
 
 Paradoxical embolus 
 
           Atrial septal defect/ASD 
 
           Patent foramen ovale 
 
 
B.UNCOMMON /RARE CAUSES       
       
(a)HYPERCOAGULABLE STATES 
 
 Deficiency of protein C/ ProteinS/ Antithrombin III 
 
 Antiphospholipid antibody syndrome 
 
 Factor V Leiden mutation 
 
 Prothrombin gene G20210 mutation 
 
 Systemic lupus erythematosus 
 
 Systemic malignancy 
 
 Sickle cell anaemia 
 
 Homocysteinemia 
 
 β Thalassemia 
 
 Polycythemia vera 
 
 Thrombotic thrombocytopenic purpura/TTP 
 
 Disseminated intravascular coagulation/DIC 
 
 Nephrotic syndrome 
 
 Inflammatory bowel disease 
 
 Oral contraceptives 
 
(b) Venous sinus thrombosis 
 
(c) Fibromuscular dysplasia 
 
(d) Vasculitis 
 
 Systemic vasculitis (Polyarteritis nodosa/PAN , Wegner’s  
 
granulomatosis, Takayasu’s andgiant cell arteritis ) 
  Primary CNS vasculitis 
 
 Meningitis (tuberculosis, fungal, bacterial, zoster,syphilis) 
 
 
(e)Cardiac causes 
 
  Calcified  mitral valve 
 
 Atrial myxoma or other Intracardiac tumour 
 
 Libman sacks endocarditis 
 
 Marantic endocarditis 
 
 
 
(f)Subarachnoid haemorrhage leading to vasospasm 
 
(g) Drugs : including Cocaine, amphetamine 
 
(h) Pregnancy-Eclampsia 
 
(i) Moyamoya disease 
 
 
 
 
  
3.1.6 DEFINITIONS 
 
TIA : when all neurological signs and symptoms resolve within a period of 24 
hours irrespective  of the presence or absence of imaging evidence of new 
permanent brain injury.
10,12 
 
 
 STROKE: is said to have occurred if the neurological signs and symptoms last 
for more than 24 hours.10,12 
 
 
3.1. 7CLASSIFICATION 
 
 
          The Oxfordshire Community Stroke Project 
12
 classifies stroke into 4 
syndromes based upon clinical features. Once the stroke lesion is complete and 
before resolution of any of the signs,the positive and negative predictive values 
against brain imaging  is good. 
 
 
  
  
  
 3.1.7: TABLE 1: RISK FACTORS OF STROKE 
 
 
3.2 PLATELETS
 
 
     Platelets are small in size and are anucleate. They play a central role in 
haemostasis as well as thrombosis
16
. Addison described platelets as  “extremely 
minute”  granules. The term ‘platelet’ was coined by Bizzozero. He described 
their adhesive property as “increased stickiness” on damage of vessel wall”. 
 
 
     Platelets form from the cytoplasm of megakaryocytes. They are discoid in  
shape and have an average size of 2µm. Younger platelets are functionally more  
able. Each megakaryocyte forms around 10
3 
 platelets and 10
11
 platelets are  
replenished daily
17
. 
 
 3.2.1 PLATELET FORMATION 
 
     3.2.1. a. Megakaryocyte Development 
 
     Megakaryocytes are myeloid cells (<1% of myeloid cells) present mainly in 
the  bone marrow. They are also present in the lung and peripheral blood. 
During  development, megakaryopoiesis occurs initially within the foetal liver 
and  yolk sac. Megakaryocytes arise from pluripotent stem cells that develop 
into 2 types of precursors: burst forming cells as well as colony forming cells. 
Both precursors express CD34 antigen
64
. Thrombopoietin(TPO) is primary 
regulator of thrombopoiesis,which is presently only known cytokine required 
for megakaryocytes to maintain a constant platelet mass. TPO acts in 
conjunction with other factors like IL-3, IL-6, and IL-11,which are not a 
necessity for megakaryocyte maturation
64
. 
     
 3.2.1b THE FLOW MODEL OF PLATELET FORMATION 
          The mechanism of  in platelet synthesis is still not known clearly. Recent 
research and evidence   favours a modified flow model. In this model,  platelets 
are thought to assemble along intermediate pseudopodial extensions . These 
extensions are known as proplatelets. These proplatelets form as a result of 
outflow and evagination of  internal membrane system of the mature 
megakaryocyte. Wright introduced the concept that platelets arise from 
megakaryocyte extensions in 1906. He described this as the detachment of 
platelets from megakaryocyte pseudopods
64
. Recent studies have supported this 
concept of platelet fragmentation from the ends of megakaryocyte extensions
64
. 
 
     The formation of platelets from megakaryocytes involve an elaborate 
procedure, converting the cytoplasm into 100- to 500-µm long branched 
proplatelets  upon which the individual platelets develop. The process of 
proplatelet and platelet formation commences at a single site on the 
megakaryocyte where one or more broad pseudopodia form. The pseudopodial 
extension elongate over a period of four to ten hours. They taper into 
proplatelets with an average diameter of 2 to4µm64. Proplatelets have multiple 
bulges or swellings , each of which is similar in size to a platelet.This gives the 
appearance of beads connected by thin cytoplasmic threads. The generation of 
proplatelets continue to spread in a wave like manner throughout the cell until 
the whole of the megakaryocyte cytoplasm is transformed into an extensive 
network of interconnected proplatelets. The nucleus of megakaryocyte shrinks  
into a central mass with scanty cytoplasm and it is finally extruded. swellings 
develop at the proplatelet ends, which are the main sites of platelet assembly 
and release, unlike swelling along the proplatelet shaft
64
. 
  
 
Figure5: anatomy of  proplatelet- differential interference contrast image 
of  proplatelets showing features of proplatelets  like tip, shaft, swellings, 
and branch point
64
 - mouse megakaryocyte  
 
3.2.2 PLATELET LIFE SPAN 
     The average lifespan of platelets is 7-10 days. They are removed from  
circulation via two mechanisms. One is by senescence in which senescent cells 
are destroyed mainly by splenic macrophages. The larger blood flow of liver 
permits a faster removal of the damaged platelets by hepatic macrophages
17
. 
Aging platelets have lesser  amounts of sialic acid and more of surface IgG
18
. 
The other way of removal is random removal in  endothelial supportive 
functions of a fixed fraction of platelets amounting to almost 7.1x10
9
/l per day.  
      
3.2.3 LIGHT MICROSCOPY 
          Under the light microscope, smears stained with Wright stain under the 
light microscope  reveals  that platelets are small, anucleate with few reddish 
granules.  They exhibit considerable variation in size as well as shape. They 
measure 2µm in  diameter19,20. 
 
Figure6: microscopic appearance of platelet in Leishman stained 
smear (x1000) 
 
  
3.2.4 ELECTRON MICROSCOPE ANDSUBCELLULAR 
FEATURES 
 
     Platelets have two forms- resting and activated. The resting state has baseline  
metabolism. The activated state is as a  result of agonist stimulation                       
(i.e thrombin). Platelets have a change in structure during the transition from 
resting to activated state. Transmission electron microscopy reveals major 
information regarding platelet anatomy.  
 
  3.2.5 
 
PLATELET SURFACE 
 
     Plasma membrane: It is  20nm thick and trilaminar
22
. Though the overall 
appearance is similar to that of other blood cells23,it hasa much more complex  
composition and function. It incorporates a variety of glycoproteins along with 
lipids onto phospholipid bilayer and it coordinates a variety of extra and intra- 
platelet events which include permeability,adhesion, activation and 
aggregation
24
. 
     Glycocalyx: It is a fuzzy layer composed of lipids, proteins, and sugars. It is   
about 15to 20 nm in thickness. It  coats outside of plasma membrane. It interacts  
with the plasma as well as the cellular components of blood and blood vessels. 
 The layer acts as a transfer point for plasma proteins like fibrinogen, as they are  
taken up into secretory granules by endocytosis
25,26
. 
     It is rich in mucopolysaccharides, glycoproteins, glycolipids, ,and  plasma  
proteins that are absorbed
27,28
. This gives a net negative surface charge, mainly 
because of  te prescence of sialic acid residues on proteins such as gpIb
29
. A net 
negative charge prevents binding of circulating platelets to each other and also 
to the vessel wall
30
. 
 
3.2.6 THE MEMBRANOUS SYSTEMS OF PLATELET 
     Platelets have properties similar to that of muscle cells such as high content  
of actin and contractile response on activation. There are two membranous 
systems  in platelets. One is surface connected canalicular system [SCCS] 
which resemble  transverse tubules. The other is dense tubular system which 
resemble sarcotubules. They have muscle like properties
23
 
 
 Fig 7:Subcellular organization of  resting platelet-  electron microscopy 
view. The marginal microtubule band encircling cytoplasm of  platelet to 
maintain discoid shapeof platelet. α-granule forms the majority of  storage 
granules. Dense granules, mitochondria, peroxisomes and lysosomes are 
interspersed
65
. 
 
Three main structural zones 
      1. Peripheral 
        2. Membranous 
        3. Organelle 
 
 
 
 
Fig 8: structural zones of platelet 
 
Table 2: structural zones of platelet 
 
  
Peripheral Zone  Membranous Zone Organelle Zone 
>  function is adhesion and aggregation, 
responsible for cell's negative charge 
> Glycocalyx  (exterior coat) 
             - consists of coagulation factors (I, II, 
VII, IX, X) 
             - Receptors (Glycoproteins Ib/IX, 
IIb/IIIa)) 
> Membrane 
 - phospholipids and proteins embedded within it 
  -  the location of pumps, channels, receptors, 
enzymes, and structural proteins 
-  Responsible for the release of fatty acid 
derivatives 
                             
function is structure and support 
         > OCS (Open Canalicular 
System) 
 
             - responsible for the secretion 
of granule contents 
         > DTS (Dense Tubular System) 
             - responsible for the storage of 
calcium 
              
             - major site  of prostaglandin 
and thromboxane synthesis 
function is secretion and 
storage 
          > Mitochondria 
          > Glycogen   
          > Granules, which 
serve as storage sites for 
proteins and other substances 
necessary for platelet function 
3.2.7 PLATELET CYTOSKELETON 
     
 
     The cytoskeleton of platelet is composed  of cytoplasmic framework of 
monomers, tubules and filaments32. The function of cytoskeleton include 
production of shape change, formation of extracellular extensions, collection 
and extrusion of secretory granules. They also affect surface activity. There are 
three different structures in the cytoskeleton which are responsible for  the 
above functions. First is the membrane skeleton buttressing  the  inner side of 
plasma membrane.  Second is actin and intermediate filaments, which  fill up 
the cytoplasm .Cytoplasmic actin filaments is otherwise known as the sol-gel 
zone . Third is the circumferential band of microtubules which encircle the 
substance of the platelets to form the resting disc like state
32,33
. 
 
3.2.8 PLATELET GRANULES AND ORGANELLES 
 
3.2.8 A) PLATELET GRANULES 
     Any given stimulus need to be amplified or accentuated to get  an  Adequate 
platelet functional response. For this, platelets possess certain  secretory granule 
which  release stimulatory materials that have been previously sequestered 
within the resting platelets.  Granules are of two types:  α granules and  dense 
bodies. They are the main effectors because of  their highly reactive and easily 
available contents [eg:Adenosinediphosphate(ADP) , fibrinogen]
34
.   The 
granule secretion initiates with a drastic increase of  platelet metabolic activity, 
which is started by a wave of calcium release and it is marked by an increased 
adenosine diphosphate (ADP) synthesis
35,36
. 
 
Table : 3 
 
 
 
 
  
 
  
3.2.8B) ORGANELLES 
 
Microperoxisomes: rare small (90nm diameter) granules and due to their 
catalase  activity, they can be demonstrated with alkaline diaminobenzidine38. It 
may be involved in synthesis of platelet activating factor. Its final role in the  
platelet cytoplasm is yet to be found out
39
. 
 
Coated vesicles: they are 70 to 90nm in diameter. They are recognized 
by their electron dense coat. The polyhedral surface coat is formed of 
clathrin.the coat that is found over the coated pits and vesicles are the same as 
that on the plasma membrane and SCCS membrane. 
 
Mitochondria: platelet mitochondria are smaller in size but are similar to  
mitochondria present in other cells. There are about seven mitochondria per  
platelet. They are the sites for the respiratory chain and the citric acid cycle
41
.  
Platelets also contain glycogen in small particles or in masses of closely related  
particles, that play an important role in platelet metabolism
42
. 
 
3.2.9 PLATELET FUNCTION 
            Platelet functions include shape change and spreading, adhesion,  
aggregation,secretion, procoagulant action, and clot retraction. 
Adhesion: following vascular insult, the initial event is platelet adhesion on to 
the  exposed subendothelial matrix. Glycoprotein receptors on platelets  ediates 
this adhesion. This depends upon the rate of shear. Recruitment of circulating 
platelets onto the thrombus
43
is also due to this adhesion. 
          Shape change,  spreading: activated platelets become spherical.   
They extend pseudopodia which helps in attaching to other to other platelets as 
well as to the blood vessel wall. The transition to a sphere increases its optical 
density. The  termed ‘shape -change’is used for this transition. An increase in 
density may also be due to other causes. So a scanning  electron microscopy 
should support this. Shape change is due to phosphorylation of myosin light 
chains. An increase  in the intracellular calcium ions activate myosin light chain 
kinase which causes phosphorylation. Inhibition of myosin light chain 
phosphatase, regulated downstream of Rho kinase
43
 also favours  
phosphorylation.  
 
Aggregation: it is the cross linking of platelets through binding of fibrinogen, 
or other bivalent or multivalent ligands like vWF to the integrin αIIbβ3 on 
adjacent cells
43
. 
 
 
  
 Fig 9:Formation of a Hemostatic Platelet Plug 
 
 
 
 
                     
  
   
            
3.2.10 PLATELET INDICES 
     Several indices are derived from platelets. The most commonly used are the  
mean platelet volume (MPV), and the platelet distribution width(PDW). Recent  
advances have made it possible to measure various platelet parameters like 
PDW,  MPV, PCT, and P-LCR with automated blood cell analysers. These 
parameters  provide important information but are yet to be accepted for routine 
clinical use
44
.  
 
 
 
3.3 MEAN PLATELET VOLUME 
          Measuring the peripheral blood platelet count reveal little about platelet  
related haemostatic properties unless the count is very low. But, the MPV gives  
useful clinical as well as patho- physiological information about patients and  
vascular diseases
8
. 
 
3.3.1 PHYSIOLOGY OF PLATELET SIZE 
MPV appears to be a marker or determinant of platelet function. In vitro 
studies have shown that large platelets are more reactive than small platelets. 
Larger platelets more readily and preferentially aggregate in response to platelet  
agonists -ADP, collagen, and adrenaline. This  produe  more prothrombotic and 
 vasoactive substances  like arachidonic acid metabolites (eg:thromboxane A2), 
serotonin, β thromboglobulin and ATP. Larger platelets also have more of dense  
granules and higher LDH activity
8
. Larger platelets  also have  a decreased 
bleeding time which is a measure of invivo haemostatic function
7
.  
 
Large platelets also express more of adhesion molecules like P-selectin, 
GPIIb/IIIa although the surface density remains a constant
8
. MPV correlates 
with platelet aggregation. This is true with measurements in platelet rich plasma 
as well as whole blood. The same holds true for population of subjects or in 
some disease states like diabetes mellitus
8
.  
 
   
  
 Fig 10: Platelet formation –platelet budding from the megakaryocyte 
surface, cytoplasmic fragmentation via the demarcation membrane system 
(DMS), proplatelet formation 
 
          When there is an acute platelet destruction without  platelet production,  
MPV increases but the MK ploidy remains the same. When there is only 
increased  platelet production, MK ploidy increases. When both production and 
destruction  coexist, there is an increase in both the MPV as well as the MK 
ploidy. This  signifies that MPV and MK ploidy may change together or 
independent of each other depending upon the varying haemostatic demands. 
This has led researchers to think that regulation of MPV and MK ploidy and 
therefore platelet count are  under separate hormonal control.  Variations in 
MPV is due to a change in the  rate of platelet destruction but altered MK ploidy 
and changes in MK size and  cytoplasmic volume are due to a change in the rate 
of platelet synthesis
7
.  
 
  
  
 
3.3.4 NORMAL MPV VALUES 
          The normal range is yet to be correctly established. Studies measuring  
MPV  in samples anticoagulated with sodium citrate suggest a normal range of 
4.5-8.5  fL with a mean of 6.5fL8. the day to day variation in MPV is small 
(CV=2.1%) when  compare with platelet count (CV=6.1%)
8
 
 
 3.3.5 MPV AND STROKE 
          In some pathological conditions, the MPHA is acutely or chronically 
perturbed leading to the formation of hyperfunctional platelets, resulting in 
vascular disease or thrombotic events like stroke. There is  evidence  supporting 
accentuated  platelet function in acute ischemic stroke
7
. 
 
The basic issue to be addressed  is whether the increased platelet function 
precedes the onset of stroke thereby playing a causative role or whether it is a 
reactive change . Information on this is gathered by studying  MK’s and  
platelets in the acute stage (within 36 hours  of onset). MPV  measured at this 
stage may well reflect the potential reactivity of platelets prior to the occurrence 
of the stroke. Since the dynamics of platelet consumption and production in the 
acute phase of  ischemic stroke are still under study, it is impossible to fully rule 
out the fact that MPV is modified  by the acute destruction of platelets and 
subsequent changes in the fragmentation of MK cytoplasm. If MK parameters 
can be shown  to be abnormal immediately following the occurrence of stroke, 
it would be strongly suggestive of a chronic perturbation of MPHA before the 
occurrence of  stroke
7
. 
 
Stroke risk factors like diabetes mellitus, hypertension, smoking and 
hypercholesterolemia, and in certain vascular conditions associated with stroke , 
such as atherosclerosis and  myocardial infarction  have shown an icreased 
platelet function leading to a shift in the MK indices in a prothrombotic  irection 
. So it seems possible  that in patients with certain risk factors , systemic platelet 
activation precedes stroke
7
.  
          There have been many studies correlating  MPV and ischaemic  stroke. 
O’malley et al studied 58 patients. Platelet variables were  assayed in the acute 
(<48 hours of stroke) and chronic(>6 months)  phases of ischaemia and 
compared it to that of age and sex matched controls. MPV  was found to be 
higher in cases than in the controls. He also showed that MPV showed no 
significant change from the acute phase in those who survived. The study thus  
concluded that there is an increase in MPV and reduced platelet count in acute 
ischemic stroke  and that it persist long after acute event. These observations are 
suggestive of a  role of larger platelets in the genesis of cerebral thrombosis and 
are likely to  represent changes occurring at thrombopoiesis
1
. 
     A substudy of  The Perindopril Protection Against  Recurrent Stroke Study 
[PROGRESS ] was done by   Philip Bath et al
4
 . 3134 cases of  this study  were 
followed up for an average time  period of 3.9 years to assess the  correlation 
between MPV and ischaemic stroke.  The study population  had a mean age of 
65 years and  71% were  males. The average MPV was found to be  10.0 fL. 
The study concluded a positive orrelation between MPV and risk of stroke. 
There was a 11% increased relative risk  of stroke per femtoliter increase in 
MPV. Perindopril donot alter MPV. The study concluded MPV as an 
independent predictor of risk of stroke amongst individuals with a prvious  
history of stroke . Therefore  measuring MPV may be  useful prognostically in 
patients with a previous history of cerebrovascular disease4. There are few 
similar studies supporting and refuting the association between MPV and 
ischaemic stroke. 
 
3.3.6 MPV AND ANTIPLATELET DRUGS 
 
          Platelet aggregation is an important step in hemostasis and is involved in  
vascular events like atherosclerosis, arterial thromboembolism, unstable angina,  
myocardial infarction, transient ischemic attacks and stroke
48
. Inhibition of  
platelet aggregation by antiplatelet drugs like aspirin has become important in 
the  treatment of above conditions. Aspirin irreversibly inhibits cyclooxygenase 
and  inhibits platelet aggregation. It is still not clear whether this impairment of  
function due to aspirin influences the feedback control of platelet production 
and  therefore the platelet count and platelet volume. Studies have shown that 
aspirin may affect the circulatory platelet mass under certain conditions
48
. 
3.3.7 MPV AND AGE 
          Though the previous thinking  was that platelet size decreases with 
age,recent research contradicts this. Recent data is in  favour of the fact that 
MPV and other related  platelet parameters and therefore the platelet protein 
content as well as reactivity are determined mainly during  or before 
thrombopoiesis by MK9. 
 
3.3.8 MPV AND GENDER 
          Few studies have shown gender dependent variations in platelet count 
with  women having higher counts than men. This might reflect the different 
hormonal  profiles or the compensatory effect associated with menstrual blood 
loss. Studies  have shown no statistically significant differences in MPV in 
males and females
49 
 
 3.3.9 MPV AND HYPERTENSION 
          MPV is shown to be significantly higher in hypertensives than in 
normotensives in some studies, but no such differences were seen for platelet  
counts
50. 
 
 
 
 
3.3.10 MPV AND DIABETES MELLITUS 
          MPV is found to be significantly higher in patients with diabetes mellitus 
and  those with impaired fasting glucose than normal individuals 51.   
 
3.3.11 MPV AND METABOLIC SYNDROME 
          The mean MPV of subjects with biochemical markers suggestive of the  
metabolic syndrome, according to the Adult Treatment Panel(ATP) III criteria, 
is  slightly higher but not significant
52
. 
 
3.3.12 MPV AND SMOKING 
          Tobacco smoking is known to accelerate atherosclerosis. Smoking 
generates  free radicals which breakdown NO, which on one hand increases 
thromboxane  production (prothrombotic action), but on the other hand 
decreases prostacyclin  synthesis (antithrombotic action). This leads to clotting 
disorder. Smoking does  not have an effect on MPV or platelet count
53
. 
 
3.3.13 MPV AND ISCHAEMIC HEART DISEASE 
          Larger platelets, being haemostatically more active, are a risk factor for  
coronary thrombosis
54
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Materials and methods 
  
4.MATERIALS AND METHODS 
 
4.1 SETTING OF THE STUDY 
 
          The study was a prospective study  conducted at Coimbatore Medical  
College, a tertiary care centre and data was collected over a period of six 
months from  December 2013 to may 2014.  The study was conducted  amongst 
100 patients diagnosed with acute ischemic stroke and who presented to the  
hospital within 48 hours of onset of symptoms. Hundred controls were also  
selected. Controls were matched for age, sex,known  risk factors including 
hypertension, diabetes, dyslipidemia, smoking,and alcoholism. The study was 
approved by the institutional ethics committee. 
 
4.2 STUDY DESIGN 
 
          The study conducted was a case control study.  
Cases definition:  rapidly developing clinical symptoms or signs of focal or 
global  loss of cerebral function with symptoms lasting for more than 24 hours 
or leading  to death with no apparent cause other than that of vascular origin 
(WHO  definition). 
     Cases included in the study were patients admitted in the medical wards  
who  were diagnosed to have stroke based on the above definition and who met 
the  inclusion criteria.   
  
Inclusion criteria: 
     1)Gender: male/ female 
     2) Age range: >20 years 
     3) Socioeconomic status: all socioeconomic groups were included. 
Exclusion criteria: 
1) Thrombocytopenia 
2) Known cases of hereditary disorders of large platelets 
3) Haemorrhagic stroke 
4) Medications reducing platelet count like hydroxyurea, antineoplastic 
agents. 
5) Patients on antiplatelet medication like aspirin, clpidogrel. 
6) Patients presenting to the institution 48 hours after the onset of the  
Symptoms. 
7) Peripheral smear showing platelet aggregates. 
8) Patients unable to communicate as a result of severe stroke or aphasia  
without a valid surrogate respondent (valid surrogate respondent is a  
spouse or first degree relative living in the same home or is self identified  
as aware of patient’s previous medical history and current treatment) 
Controls: 
Controls were selected from amongst those  patients admitted in the  
 medical wards for other diseases. Each control was matched for age(+/-
5),  sex, risk factors for stroke like diabetes mellitus, hypertension, 
smoking, alcoholism, and dyslipidemia. There was one control for each 
case recruited.  
 
Inclusion criteria:  
    1) Patients admitted to the medical wards for other diseases 
   2)  Patients attending the outpatient clinic 
 
Exclusion criteria: 
1) Thrombocytopenia 
2) Peripheral smear showing platelet aggregates 
3) Known cases of hereditary disorders with large  platelets 
4) Individuals on antiplatelet drugs 
5) Individuals on drugs like hydroxyurea, antineoplastic agents, that  
reduce platelet counts 
 
4.3) Method of data collection 
          All stroke patients admitted to Coimbatore Medical College during the 
time  period described above were assessed. Each of them were entered into a 
stroke  log. Patients fulfilling the inclusion criteria were enrolled into the study, 
after  obtaining an informed consent. Data was collected and recorded as per the  
proforma. Each patient was allotted a serial number and included into the study 
 as a case. Each case was assessed and severity of stroke assessed using the 
NIHSS. Blood sample was collected from the antecubital vein using a 5cc 
syringe. Sample was then transferred to both EDTA and citrate vacutainers. The 
samples were taken to the institutional laboratory between 2 hours and 4 hours 
of collection. Samples were analysed using Sysmex automated analyser which 
uses the technology based on electrical impedance to measure the MPV. 
Peripheral smear study was also done for each sample taken to rule out the 
presence of platelet aggregates. Patients with samples showing platelet 
aggregates were excluded from the study. The same procedures were carried out 
for obtaining samples from controls and were transferred to EDTA and citrate 
vacutainers. The samples were analysed using the same autoanalyser. Peripheral 
smear study was also carried out for each sample collected to look for the 
presence of platelet aggregates and if present were excluded. 
 
  
   4.4 SOP for cases 
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Screen case from medical                 
wards 
Eligibility,    Assessment 
Inclusion/ exclusion criteria 
 
Informed consent 
Assign serial number 
Enter patient in stroke log 
Enter patient in stroke log 
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exclusion 
History and physical 
examination 
Apply NIHSS score 
Diagnostic 
investigations as per 
protocol 
Fill  case 
report 
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4.5)PRINCIPLE BEHIND ESTIMATION OF MPV WITH SYSMEX 
AUTOMATED HEMATOLOGY ANALYSER 
 
RBC/ PLATELET DETECTION PRINCIPLE 
 
 
 
 
 
Fig:10 principle behind automated hematology analyser 
 
 
 
 
 
Fig 11: Log Gaussian platelet volume distribution curve 
 
      The MPV is directly derived from the analysis of the  platelet distribution  
curve.  The volume of each platelet is plotted on a histogram and the mean of it 
is  taken. 
 
 
 
 
  
4.6   THE NATIONAL INSTITUTES OF HEALTH STROKE SCALE 
USED TO ASSESS THE  
CLINICAL SEVERITY OF STROKE
55,56 
 
 
 
 
    
 
 
  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
4.7 INVESTIGATIONS USED FOR CASES AND CONTROLS 
 
INVESTIGATIONS 
 
CASES CONTROLS 
PLATELET COUNT 
 
YES 
 
YES 
MPV 
 
YES YES 
PERIPHERAL SMEAR 
 
YES YES 
RANDOM BLOOD 
SUGAR 
 
YES YES 
LIPID PROFILE 
 
YES YES 
CT/MRI BRAIN 
 
YES NO 
 
 
 
 
4.8 STATISTICAL METHODS 
 
Sample size: 100 cases admitted in the medical wards of Coimbatore Medical 
College, who gave consent and who met the inclusion criteria were included. 
100 controls were also selected. 
 
Data analysis: The statistical software  SPSS (version18 ) was used for  data 
analysis. Microsoft word and excel have been used to generate graphs and 
tables. 
 
  
Statistical methods: 
Descriptive statistical analysis has been carried out in this study. Results on 
continuous measurements are expressed as Mean±SD (min-max). Results on 
categorical measurements are expressed as number(%). Significance is assessed 
at 5% level of significance. Analysis of variance (ANOVA) has been used to 
find the significance of study parameters between three or more groups of 
patients, Student t test (two tailed, independent) has been used to find the 
significance of study parameters on continuous scale between two groups. A 
multivariate logistic regression analysis has been used to find out the risk 
factors associated with stroke
60,61,62and63.
 
1) Analysis of variance - ANOVA 
2) Student T test( two tailed, independent)
63
 
     3)Significant figures 
+ suggestive of significance (p value: 0.05< p<0.10) 
*moderately significant (p value: 0.01<p≤0.05) 
**Strongly significant (P value : p≤0.01) 
  
DEMOGRAPHIC DATA 
 
          472 Stroke patients admitted to the medical wards were screened to get  
 
100  cases. 
 
TABLE 4: STROKE LOG AND REASONS FOR EXCLUSION 
 
NO OF CASES SCREENED 
 
472 
NO OF CASES INCLUDED 
 
100 
NO OF CASES EXCLUDED 372 
 
 
 
 
REASONS FOR EXCLUSION 
 
Reason for exclusion 
 
number Percentage(%) 
Late presentation to hospital (>48hrs) 
 
172 46.2 
Hemorrhagic stroke 
 
60 16.1 
Delay in recruiting 
 
62 16.7 
Platelet aggregates on peripheral smear 
 
22 5.9 
No informed consent 56 15.1 
 
 
 
 
  
16.10%
16.70%
5.90%
15.10%
CHART 1: STROKE LOG AND REASONS FOR EXCLUSION
 
 
  
46.20%
late presentation to the 
hospital(>48hrs)
hemorrhagic stroke
delay in recruiting
platelet aggregates in peripheral 
smear
no informed consent
 
 
TABLE 5: AGE DISTRIBUTION 
 
 
 
The samples are age matched with p=0.944 
 
 
          The mean age for cases was 57.08±13.31, whereas for controls it was  
57.21±13.23. the maximum number of cases in this study were in the age group  
AGE IN 
YEARS 
CASES 
 
CONTROLS 
NO 
 
% NO % 
21-30 4 
 
4 4 4 
31-40 8 
 
8 8 8 
41-50 12 
 
12 12 12 
51-60 36 
 
36 36 36 
61-70 26 
 
26 26 26 
71-80 12 
 
12 12 12 
>80 2 
 
2 2 2 
TOTAL 100 
 
100 100 100 
MEAN±SD 57.08±13.31 
 
57.21±13.23 
MALE 
 
55.62±12.74 55.85±12.60 
FEMALE 
 
61.23±14.25 61.08±14.45 
P value 
 
0.064 0.083 
05
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CHART 2: AGE DISTRIBUTION
between 51 & 60, followed by 61 
23  for controls. The oldest age was 83 for cases and 84 for controls.
 
 
 
 
 
 
  
41-50 51-60 61-70 71-80 >80
age in years
-70. The youngest age was 24 for cases and 
 
 
 
 
cases
controls
74%
26%
cases
TABLE 6: GENDER DISTRIBUTION
 
74% of cases and controls were male
(61.23±14.25) with stroke were older than males (55.62±12.74)  , but this was 
not  found to be statistically significant
 
GENDER 
NO 
 
MALE 74 
 
FEMALE 26 
 
TOTAL 100 
 
Samples are gender matched with 
 
CHART 3: GENDER DISTRIBUTION
 
     
  
males
females
74%
26%
controls
 
s and 26% were females. Females 
 
CASES CONTROLS
 
% NO 
74 74 
26 26 
100 100 
 
p=1.000 
 
 
males
females
 
% 
74 
26 
100 
 TABLE 7:RISK FACTOR PROFILE 
 
     Out of the many risk factors for stroke, hypertension was the most prevalent 
in  this study group with a percentage of 53. Dyslipidemia came second with a  
percentage of 33%. Diabetes came third. 
 
 
RISK  
FACTORS 
CASES 
 
CONTROLS P value 
NO 
 
% NO %  
DIABETES 
MELLITUS 
29 29 29 29 1.000 
HYPERTENSION 53 
 
53 53 53 1.000 
DYSLIPIDEMIA 33 
 
33 33 33 1.000 
SMOKING 25 
 
25 23 23 0.741 
ALCOHOLISM 28 
 
28 28 28 1.000 
CORONARY 
ARTERY 
DISEASE 
9 9 7 7 0.019 
PREVIOUS 
STROKE 
4 4 3 3 0.121 
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CHART 4: RISK FACTOR PROFILE
 
  
TABLE 8: CLINICAL PROFILE
 
CLINICAL MANIFESTATIONS
 
Hemiplegia (motor), facial palsy
 
Hemiplegia (motor+ sensory)
 
Hemiplegia, facial palsy, homonymous hemianopia, 
aphasia 
 
Monoplegia 
Cerebellar signs 
 
                       
  
RISK FACTORS
 
 
 
 NO 
 53 
 21 
6 
8 
 
12 
 
CASES
CONTROLS
% 
53 
21 
6 
8 
12 
53%
21%
12%
8%
6%
0% 10% 20% 30% 40% 50% 60%
hemiplegia motor,facial palsy
hemiplegia motor+sensory
cerebellar signs
monoplegia
hemiplegia, motor, facial 
palsy, aphasia, homonymous hemianopia
clinical profile
CHART 5 CLINICAL PROFILE 
 
 
 
 
 
 
  
TABLE 9 
THE OXFORDSHIRE COMMUNITY STROKE PROJECT 
CLASSIFICATION OF STROKE SYNDROMES 
 
             The classification subtyped strokes on the basis of clinical criteria.  
Predominant subtype was lacunar syndromes which accounted for 66% of total  
cases, followed by POCS and PACS with 24 % and 8% each.  
 
 
STROKE SUBTYPE 
 
NO % 
LACS (LACUNAR SYNDROME) 
 
66 66 
POCS (POSTERIOR CIRCULATION SYNDROME) 
 
24 24 
PACS (PARTIAL ANTERIOR CIRCULATION SYNDROME) 
 
8 8 
TACS (TOTAL ANTERIOR CIRCULATION SYNDROME) 2 2 
 
 
 
  
24%
STROKE SUBTYPES
CHART 6 STROKE SUBTYPES
 
 
 
 
 
 
TABLE 10 : STROKE CLINICAL SEVERITY SCORE
 
NIHSS
MINOR (1-4) 
 
MODERATE (5-15) 
 
MODERATE- SEVERE (16
 
SEVERE (21-42) 
 
 
 
  
66%
8%
2%
 
 
 
 
NO 
3 
29 
-20) 21 
47 
 
LACS
POCS
PACS
TACS
 
% 
3 
29 
21 
47 
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CHART 7 STROKE SEVERITY
 
 
 
TABLE 11 :COMPARISON OF PLATELET COUNTS IN 
CASES AND CONTROLS
 
 There was a trend for lower platelet count  in cases, but this was not 
statistically significant (p= 0.178). platelet count in cases averaged
275040±123609  and that in controls averaged 298670± 123666. 
PARAMETER 
 
CASES
PLATELET 
COUNT 
 
275040±123609
(1,00,000
5,44,000)
 
Results are expressed as   MEAN± SD (min
 
MODERATE MODERATE-
SEVERE
SEVERE
29
21
47
 
 
 
 
 
 CONTROLS SIGNIFICANCE
 
 
-
 
298670±123666 
 
(1,00,000-
5,18,000) 
t=
P= 0.178
-max) 
                                                        
 
 
 
-1.351 
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TABLE 12: COMPARISON OF MPV IN CASES AND 
 
MPV( fL) 
 
CASES
EDTA 8.35±0.98
(6.4-10)
CITRATE 7.93±0.99
(6.1-9.6)
 
Results are expressed as MEAN ±SD (MIN
 
               
 
                     MPV (EDTA) and MPV citrate , both have  been  proved to have a 
statistically significant correlation with ischemic stroke with a p value < 0.001. 
The  average MPV in cases was found to be 8.35±0.98 (EDTA) and  7.93±0.99  
(citrate).  The average MPV in controls was found to be 7.81±0.79(EDTA) and 
7.30±0.74.  
298670
cases controls
CHART 8
CASES AND CONTROLS
CONTROLS 
 
 CONTROLS SIGNIFICANCE
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TABLE 13:THE OXFORDSHIRE COMMUNITY STROKE 
PROJECT CLASSIFICATION OF STROKE SYNDROMES  AND 
CORRELATION WITH MPV
          There was no statistically significant difference in MPV in each of the 
clinical subtypes of stroke. 
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(n=100)
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CHART 10  :THE OXFORDSHIRE COMMUNITY STROKE PROJECT 
CLASSIFICATION OF
STROKE SYNDROMES AND CORRELATION WITH MPV (EDTA
POCS PACS TACS
 
 
 
MPV (EDTA) MPV(CITRATE)
66 8.29±0.94 7.87±0.93
24 8.59±0.98 8.17±1.07
8 8.21±1.28 7.81±1.29
2 7.9±1.27 7.4±0.85
F=0.745           
P=0.528 
F=0.793
P=0.501
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TABLE :14 CORRELATION BETWEEN PLATELET COUNT AND 
 
Stroke subtype 
LACS 66
POCS 24
PACS 8
TACS 2
significance F=0.220
P=0.882
 
There is no statistically significant correlation between platelet count and stroke 
subtype 
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STROKE SUBTYPES 
number Platelet count
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TABLE 15:CORRELATION
 
The association between MPV 
NIHSS with corresponding mean values of MPV in each group. No statistically 
significant correlation was seen.
 
NIHSS SCORE NUMBER
N=100
1-4 
 
3 
5-15 
 
29 
16-20 
 
21 
21-42 
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SIGNIFICANCE 
 
P VALUE
 
POCS PACS TACS
STROKE SUBTYPES 
 BETWEEN STROKE –SEVERITY 
AND MPV 
and severity of stroke was studied by comparing 
 
 
 
MPV (EDTA) MPV( 
CITRATE)
7.6±0.2 7.07±0.21
8.29±0.92 7.9±0.94
8.37±0.89 7.9±0.94
8.43±1.08 8.01±1.06
 0.952 0.975 
 
 
 
 
 
 
 
 
 
 
 
 6.DISCUSSION 
 
          Previous studies have documented various platelet abnormalities in 
cerebrovascular diseases eg: circulating platelet aggregates, platelet aggregation,  
and increased release of platelet specific αgranule proteins, thereby indicating 
platelet activation. Others have shown that platelet aggregation is not increased 
in the acute phase but occurs several days after the event. This lack of detectable 
activation in the acute phase has been attributed to platelet consumption during 
the event. However, the lack of agreement between these studies may relate to 
specimen handling and different methodology. 
6.1 DEMOGRAPHIC DATA 
          The study was a prospective study carried out from December 2013 to 
may 2014 at Coimbatore Medical College Hospital. 472 patients of stroke 
admitted to the medical wards were screened to get 100 cases. 372 cases of 
stroke were excluded . Delay in presenting to the hospital (i.e 48 hours after the 
onset of the symptoms as included in the exclusion criteria) comprised of 46.2% 
of the total exclusion. Haemorrhagic stroke (16.1%), delay in recruiting 
(16.7%), absence of an informed consent (15.1%) and platelet aggregates on 
peripheral smear (5.9%) were other causes of exclusion. 
          The mean age for the cases was 57.08±13.31 when compared to 
57.21±13.23 for the controls. The maximum number of cases in the study were 
in the age group between 51 and 60. This was followed by the age group 61-70. 
The average age for the males was 55.62±12.74 when compared to 55.85±12.60 
in the controls. Females in the study population were older. Cases and controls 
comprised of 74% males and 26% females.  
Table 16 
COMPARISON OF THE DEMOGRAPHIC DATA OF THE CURRENT 
STUDY WITH THAT OF THE WESTERN LITERATURE 
STUDY 
 
 
O’Malley 
et al 
Butterworth 
et al 
Bath 
et al 
Pikija 
et al 
A.Muscari 
et al 
Current 
study 
No of cases  
Recruited 
 
58 137 301 81 137 100 
Demographics 
 
      
AGE,Y, 
MEAN±SD 
 
79.5±6.5 71.9±10.8 65±9 76 78 57.08±13.31 
WOMEN 
 
39(67%) 55(40%) 87(29%) 49(60.5%) 65(47.4%) 26(26%) 
MEN 
 
19(33%) 82(60%) 214(71%) 32(39.5%) 72(52.6%) 74(74%) 
 
Thus the mean age in our study was much lower than other studies. There is a 
clear male preponderance in the cases recruited in this study.  Other studies also 
had a similar pattern except for the studies conducted by O’Malley et al and 
Pikija et al , where a female preponderance was seen. 
6.2 RISK FACTORS FOR STROKE 
          Out of the many risk factors for stroke, hypertension was the most 
prevalent in the study group with a prevalence of 53%. Dyslipidemia came 
second with a prevalence of 33%. Diabetes mellitus came third with a 
prevalence of 29%. Similar trend was seen in the other studies as mentioned 
below  with hypertension being the most prevalent  risk factor(84.7% in 
A.Muscari et al and 82.7% in Pikija et al).  When compared to  western studies, 
the representation of previous strokes as a risk factor was only 4%. Bath et al 
had 72% of previous strokes as this study was a substudy in which the benefits 
of ACE inhibitors (perindopril) in preventing a restroke was studied. Diabetes 
mellitus had a representation of 29% of cases which was higher than most of the 
western studies. 
 
Table 17 COMPARISON OF RISK FACTOR  PROFILE OF CURRENT 
STUDY WITH WESTERN LITERATURE 
Study O’Malley 
et al 
Butterworth 
et al 
Bath 
et al 
Pikija 
et al 
A.Muscari 
et al 
Current 
study 
No of cases 
recruited 
58 137 301 81 137 100 
RISK 
FACTORS 
      
Previous 
stroke/TIA 
19(33%) - 217(72%) 23(28.4%)  4(4%) 
Hypertension 17(29%) - - 67(82.7%) 116(84.7%) 33(33%) 
Atrial 
fibrillation 
15(26%) - - 26(32.1%) 44(32.1%) - 
Previous MI 15(26%) - 24(8%) 3(3.70%) 17(12.4%) 4(4%) 
Angina 
pectoris 
16(28%) - - - - 5(5%) 
Alcohol 10(17%) - - - - 28(28%) 
Peripheral  
vascular 
disease 
7(12%) - - 2(2.47%) - - 
Smoking 8(14%) - 60(20%) 4(4.9%) 20(14.6%) 25(25%) 
Diabetes 
mellitus 
5(8.6%) - 39(13%) 15(18.5%) 29(21.2%) 29(29%) 
6.3 DRUG HISTORY 
Table 18 :COMPARISON OF DRUG HISTORY OF PATIENTS IN THE 
CURRENT STUDY WITH WESTERN LITERATURE 
STUDY 
 
O’Malle
y et al 
Butterworth 
et al 
Bath  
et al 
Pikija  
et al 
A.Muscar
i et al 
Current 
study 
No of cases 
recruited 
58 137 301 81 137 100 
Drug history       
antiplatelets 19(33%) - 211(70%) 33(40.7%) 59(43.1%) - 
Βblockers 3(5%) - - - - 10(10%) 
Diuretics 24(41%) - - - - 6(6%) 
Nitrates 7(12%) - - - - 3(3%) 
Digoxin 11(19%) - - - - 1(1%) 
Calcium 
antagonist 
4(6.8%) - - - - 16(16%) 
Statins   - 6(7.4%) - 8(8%) 
anticoagulants   - 2(2.5%) - - 
 
Eventhough there were a few cases who had prior coronary artery disease or 
strokes, none of the stroke patients recruited were on antiplatelet drugs,as it was 
one of the exclusion criteria. This was included as an exclusion criteria because 
of the concern regarding the fact that concurrent usage of antiplatelets might 
influence the MPV studied. There has been previous studies with aspirin and 
MPV and it showed no interference in vitro or in vivo. But there are other 
studies which have disproved this.  
          In this study,cases used predominantly antihypertensives with 16% of the 
hypertensives  with 16% of the hypertensives on calcium antagonists followed 
by β blockers and diuretics. 
 
6.4 PLATELET PARAMETES AND STROKE 
Table 19:Comparison of platelet parameters of the current study with 
western literature 
Study Mean platelet 
volume(EDTA),fL 
Mean platelet 
volume(citrate),fL 
Platelet count, 
x10
9
/L 
O’Malley et al 11.3±0.85(11.3±0.85)  255±88 
(299±80) 
Butterworth  
et al 
8.04±1.04(7.69±0.83) 7.35±1.05(7.09±0.74) 231±82(236±54) 
Bath et al 10.0±2.1  233±80 
Pikija et al 9.09(7.05-17.60)  197(106-637) 
A.Muscari et 
al 
8.21±1.04  244.1±86.7 
Tohji et al 9.80±0.79 
(10.72±0.63) 
 194±54(247±59 
Current study 7.86±0.82 
(7.58±0.70) 
 275±123(298±123) 
 
  
6.5. STROKE SUBTYPES AND MPV 
          The Oxfordshire Community Stroke Project classification of stroke 
syndromes  was used to classify strokes into Lacunar and Non lacunar 
syndromes (PACS,POCS,TACS). Two studies done by Butterworth et al and 
A.Muscari et al have shown statistically significant increase in MPV in non 
lacunar strokes as compared to lacunar strokes.  Study done by O’Malley et al 
did not find out any such correlation. Also, in this study no statistically 
significant correlation was found out. This study concludes that patients with 
ischaemic stroke have larger platelets , a finding compatible with other reports 
of accentuated platelet function in brain infarction, including increased blood 
and urine levels of b-thromboglobulin (b-TG)  and TxA2. However, it has not 
been possible to establish that thrombomegaly is restricted to patients with 
cortical ischaemic stroke. Cortical events are usually related to 
atherothromboembolic events that occur in the heart, aorta, carotid arteries or 
large intracranial arteries, and are likely to involve platelet activation. 
Conversely, many deep white matter lacunar strokes  are  considered to be a 
consequence of small vessel lipohyalinosis, a disease process not involving 
platelets
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6.6. STROKE SEVERITY AND MPV 
          The clinical severity of stroke at presentation  was assessed using the 
National Institutes of Health  Stroke  scale and severe  type of stroke was seen 
in 47% of cases with a score ranging from 21 to 42. 3% had only minor stroke 
with a score of 1-4,  29% had moderate stroke with a score ranging from 5 to 
15, 21% had moderate to severe stroke with a score ranging between 16 and 20. 
The association of MPV with severity of stroke was determined by comparing 
the NIHSS score with the corresponding mean values of MPV in each group.  
MPV- EDTA showed a p value of 0.952 and MPV citrate showed a p value of 
0.975, both of which were statistically insignificant. O’Malley conducted 
similar studies and assessed stroke severity using the modified Rankin’s scale. 
In that study outcomes were divided as independent (Rankin’s grade 0-2), 
dependent (Rankin’s grade 3 to 5), and dead (Rankin’s grade 6).  However, no 
statistically significant correlation with MPV was obtained. Butterworth et al 
studied patients who were dead or dependent at 3 months, using the Lindley 
score, and they had a higher platelet volume , and a tendency to a lower platelet 
count as compared to those who fared well. But statistical significance was not 
obtained. 
 
          There is indirect evidence that the changes in MPV and platelet count are 
likely to have preceded the vascular event and are unlikely to be due to platelet 
consumption at the infarct site. Because the average life span of platelets is 
about 8 days, the elevated MPV seen within the first 48 hours after stroke 
probably represent the platelets released before the infarction.  
 
          Also, it is unlikely that platelet consumption due to localized thrombosis 
would affect peripheral venous estimation of platelet variables. The observation 
that there was no difference in MPV between large cortical strokes and smaller 
lacunar infarctions also lends  support to this view. Large platelets may promote 
the thrombotic event in a susceptible individual,and  the increase in MPV may 
have contributed to the development of stroke rather than simply being a 
consequence of the acute event itself. In conclusion , this study has shown an 
increase in MPV and reduction of platelet count in acute stroke. The 
observations here suggest a role for larger platelets in the genesis of cerebral 
thrombosis and are likely to represent changes occurring at thrombopoiesis. 
Further research is required to know more about the role of platelet volume in 
stroke pathology, outcome, and most importantly , in individuals at risk for 
stroke.  
 
6.7.  LIMITATIONS OF THE STUDY 
There are a few limitations to this study that needs to be mentioned. 
1. 1.There were only 100  patients and controls in the study. Sample size 
was adequate , but was smaller than many of the western studies. 
2. 2.There was no follow up done of the cases due to time constraint. If on 
follow up a persistent increase of MPV was demonstrated, it would have 
given more strength to the hypothesis that the increase in MPV may have 
contributed to the development of stroke rather than simply being  a 
consequence of the acute event itself. 
3. Seriously ill patients directly admitted to the intensive care unit have not 
been included in the study due to difficulty in getting consent. This could 
have led to selection bias. This would have reflected upon the correlation 
of MPV and severity of stroke. 
4. The controls have been matched for age, sex ,and most of the risk factors 
like hypertension, diabetes mellitus, alcoholism  and dyslipidemia. Other 
risk factors like smoking, coronary artery disease, and previous strokes 
could not be perfectly matched, which would have been ideal. But, most 
of the western studies have also been carried out on only age and sex 
matched controls.  
  
SUMMARY 
          Cerebrovascular diseases include some of the most devastating and 
common neurological disorders. They cause approximately 200,000 deaths per 
year in the United States and are a major cause of morbidity. The prevalence of 
stroke in India was estimated as 203 per 100,000 population above 20 years, 
amounting to a total of about 1 million cases. It was found to be the sixth 
leading cause of disability adjusted life years (DALY; one DALY is one lost 
year of healthy life ) in 1990 and is projected to rank four by the year 2020
13
.  
 
          Platelets play a major role in the pathogenesis of vascular disease , and 
the mean platelet volume is a physiological variable of hemostatic importance. 
Larger platelets are more reactive, produce more prothrombotic factors 
3 and 4
, 
and aggregate more easily.  They also have more of dense granules and also 
release more of serotonin and β thromboglobulin than smaller platelets. Platelets 
lack a nucleus and their characteristics are determined by their progenitor cells, 
the bone marrow megakaryocytes. Ischaemic stroke is thought to occur as a 
result of thrombotic occlusion of a stenosed atherosclerotic blood vessel. 
Initially platelets adhere to the damaged vessel , resulting in the recruitment of 
further platelets, followed by aggregation,platelet plug formation and finally, 
thrombotic occlusion. So the detection of large platelets in patients would lend 
support to the idea that platelet volume influences thrombotic large vessel 
occlusion leading to ischaemic stroke.  
 
          Though there are quite  a few studies indicating the association of platelet 
volume with myocardial infarction, only a  very few studies have been 
conducted to find out the correlation between platelet size and ischaemic stroke. 
Also , among these studies, there have been discrepancy regarding sample size, 
the methodology used and the final results. There are no well documented 
studies in India comparing the association of mean platelet volume with 
ischaemic strokes.  This was a prospective study and data was  collected from  
December 2013 till May 2014, at Coimbatore Medical college hospital, 
Coimbatore , a tertiary care referral centre. The study was carried out among 
100  patients diagnosed to have an acute ischaemic stroke and admitted to the 
medical wards in the hospital within 48 hours of onset of symptoms  as well as 
satisfying the inclusion and exclusion criteria. The data was compared with 100 
controls matched for  age, sex ,as well as known risk factors for stroke like 
diabetes mellitus, hypertension, dyslipidemia, smoking and alcoholism.  
 
 
  
Key findings included: 
 
1) The main parameter studied was MPV. MPV has got a statistically 
significant correlation with ischaemic stroke with a p value less than 
0.001. this was true for both EDTA as well as citrate samples. The 
average MPV in cases was 8.35±0.98 (EDTA) and 7.93±0.99 (citrate). 
The average MPV in controls being 7.81±0.79 (EDTA) and 7.30±0.74 
(citrate). Therefore, the study shows  an elevated MPV  in the acute phase 
of  ischaemic stroke. Within this relationship and confounding for other 
significant  variables in the multivariate regression analysis, it can be 
stated that an increase in MPV is independently associated with stroke. 
The observations here suggest a role for larger platelets in the genesis of 
cerebral thrombosis and likely to represent changes occurring at the time 
of thrombopoiesis. Further research is required to enquire about the role 
of platelet volume in stroke pathology, outcome, and more importantly, in 
patients at risk for stroke. 
2) The platelet count in patients with stroke is lower with average being 
275±123 (100-5,44) compared to controls with an average of  
299±124(100-518). 
3) The Oxfordshire Community stroke project classification of stroke 
syndromes was used to classify strokes into Lacunar and Nonlacunar 
syndromes (POCS, PACS, TACS).The association of MPV with stroke 
subtype was assessed by comparing the stroke subtype with 
corresponding mean values of MPV’s in each group.MPV EDTA showed 
a p value of 0.523 and citrate 0.511, both of which were statistically 
insignificant. Therefore,  In this study, no statistically significant 
correlation was established between MPV and stroke subtypes. 
4) The clinical severity of stroke  at presentation was determined using the 
National Institutes of health Stroke scale and severe stroke was seen with 
47%  of cases. 3% had only minor stroke.29 % had moderate severity 
stroke and21 % had moderate to severe stroke. The association of MPV 
with severity of stroke was determined by comparing the NIHSS with 
corresponding mean values of MPV’s in each group. MPV  EDTA 
showed a p  value of 0.952 and MPV citrate showed a p value of 0.975, 
both of which were statistically insignificant.  
          In conclusion, this study has shown an elevation of MPV and a reduction 
of platelet count in acute stroke. With this relationship and confounding for 
other significant variables, an increase in MPV is independently associated with 
stroke. The observations here suggest a role for larger platelets in the genesis of 
cerebral thrombosis and are likely to represent changes occurring at 
thrombopoiesis. Further research is required to enquire into the role of platelet 
volume in stroke  pathogenesis, outcome, and more importantly in individuals at 
risk for stroke. 
  
7. CONCLUSIONS 
 
1. This study has shown an elevation of MPV in acute phase of ischaemic 
stroke. Within this relationship and adjusting for other significant 
variables in multivariate regression analysis, it can be stated that an 
increase in mean platelet volume is independently associated with stroke. 
The observations here suggest a role for larger platelets in the genesis of 
cerebral thrombosis and are likely to represent changes occurring at 
thrombopoiesis. Further research is required into the role of platelet 
volume in stroke pathology, outcome, and most importantly, in 
individuals at risk for stroke.  
 
2. This study did not find a statistically significant correlation between 
clinical severity of stroke and mean platelet volume. 
 
3. This study showed no statistically significant correlation between mean    
platelet volume and stroke subtypes. Thrombomegaly is restricted not just 
to patients with cortical ischemic stroke but is also seen with lacunar 
syndromes. 
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PROFORMA FOR CASES 
 
 A STUDY ON THE ASSOCIATION OF MEAN PLATELET 
VOLUME WITH ISCHAEMIC STROKE AND ITS 
CORRELATION WITH STROKE SUBTYPES 
                                                                                         Case no: 
Name :                                                                                          I.P. No. :  
Age :                                                                                             Date of 
Admission:  
Sex :                                                                                              Date of 
Discharge :  
Occupation :                                                                                  Unit:  
Address :  
Complaints with duration :  
History of Present illness :  
1. Weakness of limbs : Present/ Absent  
If present  
a. Limbs involved : Upper limb : Right / left Lower limb : Right / Left  
b. Mode of onset : Sudden / Insidious / Slow  
c. Duration : d. Progression :  
2. Weakness of Face : Present / Absent  
If present :  
a. Part of face involved : Upper / Lower  
b. Deviation of angle of mouth : Right side / Left side  
c. Difficulty in closing eyes : Present / Absent  
3. Level of Consciousness Alert / Drowsy / Unconscious  
4. Speech disturbances : Present / Absent  
If present :  
a. Slurring of speech : Present / Absent  
b. Comprehension : Normal / Abnormal  
5. History suggestive of Cranial nerve palsy ;  
H/o Blurring of Vision : Present / Absent  
Diplopia : Present / Absent  
Dysphagia : Present / Absent  
Nasal regurgitation : Present / Absent   
6.H/o Sensory disturbances : Present / Absent 
  
PAST HISTORY 
 
1. History of previous cerebrovascular accidents : Yes / No  
2. History of TIA : Yes / No  
3. History of IHD : Yes / No  
4. History of Hypertension : Yes / No  
5. History of diabetes mellitus : Yes / No 
6. History of RHD : Yes / No  
 
 
Personal History :  
Smoking : Yes / No  
Alcohol intake : Yes / No  
Drug history: antiplatelets, antihypertensives, chemotherapy drugs 
GENERAL PHYSICAL EXAMINATION :  
 Vital signs: Pulse : B.P. : R/R :  
 NS examination – NIHSS assessment 
CVS examination 
Respiratory system examination 
Per abdomen examination 
INVESTIGATION :  
Platelet count 
Mean platelet volume 
Peripheral smear 
Lipid profile 
Blood Glucose : FBS PPBS  
ECG  
C.T. SCAN  
NIHSS score 
 
 
 
 
PROFORMA FOR CONTROLS  
 
Name :                                                                          I.P. No. :  
Age :                                                                             Date of Admission:  
Sex :                                                   Date of Discharge :  
Occupation :                                                                  Unit:  
Address :  
 
PAST HISTORY 
 
1. History of previous cerebrovascular accidents : Yes / No  
2. History of TIA : Yes / No  
3. History of IHD : Yes / No  
4. History of Hypertension : Yes / No  
5. History of diabetes mellitus : Yes / No 
6. History of RHD : Yes / No  
Personal History :  
Smoking : Yes / No  
Alcohol intake : Yes / No  
Drug history: antiplatelets, antihypertensives, chemotherapy drug 
 
 
 
INVESTIGATION :  
Platelet count 
Mean platelet volume 
Peripheral smear 
Lipid profile 
Blood Glucose : FBS PPBS  
ECG  
 
 
 
 
  
CONSENT FORM(CASES) 
 
 Mr/Mrs/Ms……………………………………………………, 
…………….(relationship) of……………………………………(legal guardian) 
is being asked to be a participant in the research study titled ““ A STUDY ON 
THE ASSOCIATION OF MEAN PLATELET VOLUME WITH ISCHAEMIC 
STROKE AND ITS CORRELATION WITH STROKE SUBTYPES ”” in 
CMC Hospital, Coimbatore, conducted by Dr.V.BHAVANA, Post Graduate 
Student in the Department of General Medicine, Coimbatore Medical College. 
He /she satisfies eligibility as per the inclusion criteria. You/legal guardian can 
ask any question you may have before agreeing to participate. 
 
Research Being Done 
     A STUDY ON THE ASSOCIATION OF MEAN PLATELET VOLUME 
WITH ISCHAEMIC STROKE AND ITS CORRELATION WITH STROKE 
SUBTYPES 
 
Purpose of Research 
           Aim of the study is to find out the correlation between mean platelet 
volume and ischaemic stroke and to find out whether there is any 
correlation between mean platelet volume and stroke subtype as well as 
between stroke severity and mean platelet volume. 
 
     It includes details like age,sex and history of diabetes, hypertension 
,coronary artery disease, smoking and alcoholism 
 
       Investigations includes platelet count, peripheral smear, mean platelet 
volume, blood sugar, lipid profile , electrocardiogram & CT scan Brain 
Decline from Participation 
You have the option to decline from participation in the study existing protocol 
for your condition. 
 
Privacy and Confidentiality 
Privacy of individuals will be respected and any information about you or 
provided by you during the study will be kept strictly confidential. 
 
Authorization to publish Results   
Results of the study may be published for scientific purposes and/or presented 
to scientific groups, however you will not be identified. 
 
Statement of Consent 
I volunteer and consent to participate in this study. I have read the consent or it 
has been read to me. The study has been fully explained to me, and  I may ask 
questions at any time. 
 
-------------------------------                             -------------------------------   
Signature /Left thumb impression                        Date 
(volunteer)   
 
--------------------------------                            -------------------------------- 
Signature of witness                                                Date 
 
 
 
 
 
 
 
 CONSENT FORM(CONTROLS) 
 
 Mr/Mrs/Ms……………………………………………………, 
…………….(relationship) of……………………………………(legal guardian) 
is being asked to be a participant in the research study titled ““ A STUDY ON 
THE ASSOCIATION OF MEAN PLATELET VOLUME WITH ISCHAEMIC 
STROKE AND ITS CORRELATION WITH STROKE SUBTYPES ” in CMC 
Hospital, Coimbatore, conducted by Dr.V.BHAVANA, Post Graduate Student 
in the Department of General Medicine, Coimbatore Medical College. He /she 
satisfies eligibility as per the inclusion criteria. You/legal guardian can ask any 
question you may have before agreeing to participate. 
 
Research Being Done 
     A STUDY ON THE ASSOCIATION OF MEAN PLATELET VOLUME 
WITH ISCHAEMIC STROKE AND ITS CORRELATION WITH STROKE 
SUBTYPES 
 
Purpose of Research 
           Aim of the study is to find out the correlation between mean platelet 
volume and ischaemic stroke and to find out whether there is any 
correlation between mean platelet volume and stroke subtype as well as 
between stroke severity and mean platelet volume. 
 
     It includes details like age,sex and history of diabetes, hypertension 
,coronary artery disease, smoking and alcoholism 
 
       Investigations includes platelet count, peripheral smear, mean platelet 
volume, blood sugar, lipid profile , electrocardiogram. 
 
Decline from Participation 
You have the option to decline from participation in the study existing protocol 
for your condition. 
 
Privacy and Confidentiality 
Privacy of individuals will be respected and any information about you or 
provided by you during the study will be kept strictly confidential. 
 
Authorization to publish Results   
Results of the study may be published for scientific purposes and/or presented 
to scientific groups, however you will not be identified. 
 
Statement of Consent 
I volunteer and consent to participate in this study. I have read the consent or it 
has been read to me. The study has been fully explained to me, and  I may ask 
questions at any time. 
 
-------------------------------                            -------------------------------   
Signature /Left thumb impression                        Date 
(volunteer)   
 
--------------------------------                           -------------------------------- 
Signature of witness                                                Date 
  
xg;g[jy;  gotk;; [ ; ;; [ ; ;; [ ; ; 
bgah; : 
ghypdk; :        taJ : 
Kfthp : 
 
 muR nfhit kUj;Jtf; fy;Y}hpapy; bghJ kUj;Jtj; Jiwapy; 
gl;l nkw;gog;g[ gapYk; khztp nkw;bfhs;Sk;  ",uj;j czh;t[ ; ; [; ; [; ; [ bry;ypd; ; ;; ;; ;
mst[ kw;Wk; gf;fthj nehapf;Fk; ,ilna cs;s rk;ke;jj;ij mwpjy; [ ; ; ; ; ; ; ; ; ; ;[ ; ; ; ; ; ; ; ; ; ;[ ; ; ; ; ; ; ; ; ; ;
vd;w jiyg;gpy;; ; ;; ; ;; ; ;" Fwpj;j Ma;tpy; bra;Kiw kw;Wk; midj;J 
tptu';fisa[k; nfl;Lf; bfhz;L vdJ re;njf';fis bjspt[g;gLj;jpf; 
bfhz;nld; vd;gij bjhptpj;Jf; bfhs;fpnwd;. 
 
 ehd; ,e;j Ma;tpy; KG rk;kjj;JlDk;/ Ra rpe;jida[lDk; 
fye;J bfhs;s rk;kjpf;fpnwd;. 
 
 ,e;j Ma;tpy; vd;Dila midj;J tpgu';fs; 
ghJfhf;fg;gLtJld; ,jd; Kot[fs; Ma;tpjHpy; btspaplg;gLtjpy; 
Ml;nrgid ,y;iy vd;gij bjhptpj;Jf; bfhs;fpnwd;. ve;j neuj;jpYk; 
,e;j Ma;tpypUe;J ehd; tpyfpf; bfhs;s vdf;F chpik cz;L 
vd;gija[k; mwpntd;. 
 
,lk;  :       ifbahg;gk; / nuif 
ehs; : 
 
 
 
 
  
Sl.No Name Age Sex Risk factors Clinical profile 
Stroke 
subtype 
NIHSS PLT MPV 
        DM HTN D S A CAD Stroke         EDTA Citrate 
                                  
1 MURUGAN 31 M       P P     FP, Motor LACS 
17  mod-
severe 1,00 8.3 7.8 
2 DURAI 33 M   p           FP, Motor LACS 37  severe 150 7.3 7 
3 SAMPATH 43 M   p   p       cerebellar POCS 
18 mod-
severe 300 8.6 8.2 
4 MUNIYAN 48 M   p   p p     hemi,FP,HH,Aphasia TACS 32 severe 256 8.8 8 
5 PAPPATHI 57 F p   p         motor,sensory LACS 8  mod 320 9.8 9.4 
6 AKBERUDDEEN 52 M p p           FP, Motor POCS 5 mod 222 8 7.2 
7 SHANMUGAM 55 M   p           FP, Motor LACS 4 minor 122 7.4 6.9 
8 ROSEN BEEVI 60 F   p           FP, Motor LACS 
18 mod-
severe 256 7.8 7.6 
9 GOVINDRAJ 55 M p p           cerebellar POCS 22 severe 117 8.9 8.5 
10 PALANISAMY 60 M p p           FP, Motor POCS 12 mod 120 8.9 8.3 
11 RAJU 55 M               FP, Motor LACS 30 severe 123 7 6.5 
12 KUMAR 60 M   p           motor,sensory LACS 6 mod 145 7.8 7.6 
13 DEVANAGAI 67 F   p p   p     hemi,FP,HH,Aphasia POCS 23Severe 236 9.4 9 
14 PAUL RAJ 68 M   p         p FP, Motor LACS 
17mod-
severe 290 8.1 7.9 
MASTER CHART - CASES 
15 SENTHIL  63 M       p p     FP, Motor LACS 28 severe 389 9.5 9.1 
16 MADHAN 64 M   p     p     FP, Motor LACS 38 severe 106 7.4 7 
17 SUBRAMANI 69 M   p p         FP, Motor LACS 25 severe 114 9.5 8.7 
18 RAMASAMY 72 M       p       FP, Motor LACS 
20 mod-
severe 180 8.8 8 
19 KANNAMAL 77 F   p           hemi,FP,HH,Aphasia TACS 35 severe 320 7 6.8 
20 GOPAL 83 M p             FP, Motor LACS 29 severe 209 6.9 6.8 
21 PAPPAMMAL 35 F     p         cerebellar POCS 
20 mod-
severe 187 8.4 7.7 
22 RAJA 39 M   p   p   p   motor,sensory LACS 28 severe 176 7.5 7.3 
23 TAMIL ARASU 44 M   p p p       motor,sensory LACS 
16 mod-
severe 390 9.6 9.1 
24 CHINNAMMAL 49 F   p           FP, Motor LACS 26 severe 187 7.9 7.3 
25 KUPPUSAMY 56 M   p   p        monoplegia  PACS 8 mod 389 9.4 9.2 
26 SURESH 51 M p       p     motor,sensory LACS 31 severe 400 7 6.8 
27 SHANTHI 56 F p   p         FP, Motor LACS 8 mod 500 7.8 7.5 
28 MOHAMED 51 M   p     p     FP, Motor POCS 7 mod 200 8.7 8.4 
29 PRABHU 56 M   p p p       hemi,FP,HH,Aphasia POCS 25 severe 310 9.8 9.6 
30 SHANKAR 51 M   p     p     FP, Motor LACS 
18 mod-
severe 215 7 6.3 
31 RAMKUMAR 56 M   p p   p     motor,sensory LACS 35 severe 346 7.9 7.5 
32 ANNADURAI 63 M         p     motor,sensory LACS 8 mod 216 8.9 8.6 
33 BALA SUNDARAM 68 M p   p          monoplegia  PACS 
17mod-
severe 310 6.8 6.3 
34 DHANALAKSHMI 67 F     p         cerebellar POCS 
18 mod-
severe 387 8.8 8.2 
35 PERIYASAMY 62 M   p p   p     cerebellar POCS 40 severe 540 6.6 6.1 
36 RAJENDRAN 65 M   p     p     motor,sensory LACS 36 severe 322 8 7.5 
37 JOTHI 70 F   p           cerebellar POCS 24 severe 322 9 8.8 
38 RAJAMMAL 73 F               motor,sensory LACS 22 severe 544 8.9 8.8 
39 VENKATESH 78 M     p p p      monoplegia  PACS 12 mod 145 9.5 9.1 
40 DEVAN 36 M p   p         FP, Motor LACS 40 severe 233 7.5 7 
41 TAMIL SELVAN 32 M     p p p     FP, Motor LACS 
19 mod-
severe 320 7.9 7.3 
42 RAMALINGAM 45 M p     p p     motor,sensory LACS 21severe 200 9.8 9.3 
43 KUMARI 50 F     p          monoplegia  PACS 6mod 320 6.5 6.1 
44 ERUSAN 55 M   p     p     motor,sensory LACS 13 mod 210 8.7 8.3 
45 PERIYAN 52 M   p p   p     FP, Motor LACS 33 severe 322 8 7.7 
46 RAJESWARI 57 F p             FP, Motor LACS 10mod 432 8.4 8.3 
47 RAJA 52 M   p           FP, Motor LACS 10 mod 210 9.8 9.5 
48 GOTHANDAM 57 M   p   p p     FP, Motor LACS 29 severe 322 6.4 6.1 
49 SIVA 52 M       p        monoplegia  PACS 4 minor 106 7.8 7.3 
50 LOGANATHAN 57 M p   p     p   FP, Motor POCS 26 severe 150 8.8 8.5 
51 LAZER 64 M       p       FP, Motor LACS 
17 mod-
severe 178 9.8 9.6 
52 MARIMUTHU 69 M   p   p p     FP, Motor LACS 10 mod 288 6.6 6.4 
53 JAMES 66 M p             motor,sensory LACS 22 severe 100 8.8 8.4 
54 SIVALINGAM 61 M p p           motor,sensory LACS 39 severe 207 8.8 8.5 
55 SANTHANAM 66 M     p p       hemi,FP,HH,Aphasia POCS 35 severe 365 8.8 8.4 
56 LAKSHMI 76 F               motor,sensory LACS 23Severe 508 9.3 8.9 
57 MANI 74 M   p p p   p   FP, Motor POCS 5mod 100 7.4 7.1 
58 PARVATHY 79 F p             FP, Motor POCS 
20mod-
severe 190 9.6 9.4 
59 RANI 38 F   p p         FP, Motor LACS 38severe 367 7.6 7.1 
60 MOHANNA 46 F   p p         motor,sensory LACS 22severe 540 10 9.6 
61 ARUMUGAM 42 M   p           cerebellar POCS 
18 mod-
severe 123 6.8 6.3 
62 MANIKANDAN 54 M   p   p       motor,sensory LACS 
16 mod-
severe 245 8.2 7.4 
63 MARIYAPPAN 53 M   p p     p   motor,sensory LACS 35 severe 238 8.6 8.2 
64 MANIKAM 58 M   p     p     motor,sensory LACS 12 mod 190 9.6 9.4 
65 RAJIV 53 M             p FP, Motor LACS 13 mod 289 7.5 7.1 
66 BALAMURUGAN 58 M p     p       FP, Motor LACS 24 severe 489 8 7 
67 RAMARAJ 53 M   p p p       FP, Motor LACS 22 severe 287 8.6 8.3 
68 THANGARAJ 58 M   p   p       FP, Motor LACS 38 severe 156 9.8 9.5 
69 SELVARAJ 65 M     p         cerebellar POCS 
18 mod-
severe 288 7.8 7.7 
70 MUTHURAJ 70 M   p           FP, Motor LACS 13 mod 299 7.8 7.5 
71 SHAJAHAN 65 M p   p         FP, Motor POCS 25 severe 478 8.5 8.6 
72 KANDASAMY 62 M p         p   FP, Motor LACS 38 severe 389 8.6 7.9 
73 RANGAN 67 M   p p   p     FP, Motor LACS 30 severe 229 9.8 9 
74 GOMATHY 78 F p              monoplegia  PACS 15 mod 346 8.5 8 
75 KOKILAVANI 75 F   p       p   cerebellar POCS 15 mod 209 7.3 6.4 
76 PALANI 80 M   p           motor,sensory LACS 25 severe 280 7.3 7 
77 PALANIAPPAN 40 M   p p          monoplegia  PACS 10 mod 308 7.4 7.2 
78 GOWRI 42 F p p p       p FP, Motor LACS 22 severe 416 8.5 8 
79 MAHESWARI 47 F               cerebellar POCS 30 severe 267 9.6 9.4 
80 GANESH 44 M     p p p     motor,sensory LACS 10 mod 370 8.8 8.1 
81 SARAVANAN 53 M p   p p p     FP, Motor LACS 4 minor 408 7.6 7 
82 ANTONY 54 M p p         p FP, Motor POCS 38 severe 166 9.8 9.3 
83 MUNUSAMY 54 M p   p     p   FP, Motor LACS 15 mod 295 7.8 7.7 
84 BASHEER 59 M   p p   p     FP, Motor LACS 32 severe 232 7.8 7.2 
85 SELVAMANI 54 M p              monoplegia  PACS 5 mod 267 9.8 9.3 
86 SUDHA 59 F   p           cerebellar POCS 39 severe 289 7.2 6.6 
87 PONNUSAMY 66 M p p     p     FP, Motor LACS 
20 mod-
severe 104 8.8 8.7 
88 VELADURAI 69 M       p p     FP, Motor LACS 
16 mod-
severe 328 8.4 7.8 
89 BANUMATHI 64 F   p           hemi,FP,HH,Aphasia POCS 26 severe 507 9.9 9.2 
90 THANGARAJ 63 M               FP, Motor LACS 40 severe 378 10 9.4 
91 MANIKAM 68 M p             cerebellar POCS 26 severe 104 9.6 9.3 
92 RAMANI 71 F p         p   FP, Motor LACS 
18 mod-
severe 246 9.8 9.1 
93 GANDIMATHI 76 F p       p     FP, Motor LACS 
18 mod-
severe 209 7.8 7.4 
94 KAVITHA 82 F   p           FP, Motor LACS 28 severe 489 6.5 6.2 
95 RANGARAJ 28 M               FP, Motor LACS 6 mod 326 7.8 7.3 
96 VELUSAMY 27 M p             FP, Motor LACS 7 mod 389 8 7.5 
97 ARIVALAGAN 24 M               FP, Motor LACS 10 mod 489 7.9 7.4 
98 AZHAGARASAN 26 M         p     FP, Motor LACS 15 mod 165 8.2 7.6 
99 MUTHULAKSHMI 41 F           p   FP, Motor LACS 
20 mod-
severe 399 8.6 8.1 
100 DURAISAMY 60 M   p p         motor,sensory LACS 6 mod 172 7.8 7.6 
                            117.2183     
 
sl no name age sex risk factors 
MPV 
EDTA 
MPV 
citrate 
PLT 
count 
        DM D HTN S A CAD Stroke     
1 AROKIYASAMY 32 M       p       8 7.4 1,88,000 
2 VELUSAMY 40 M   p p   p     7 6.6 1,89,000 
3 VELUMURUGAN 45 M p     p       8.3 7.8 2,30,000 
4 MURUGAN 43 M     p   p     7.6 7.6 3,08,000 
5 SHANTHA 56 F     p       p 8.1 8.1 4,89,000 
6 LINGAN 53 M   p p         8.2 7.8 1,45,000 
7 LOGANATHAN 57 M p   p   p     7.1 6.5 3,99,000 
8 MYLATHAL 60 F p p p         7.5 7.2 1,22,000 
9 SELVARAJ 56 M     p         8.6 8.1 3,80,000 
10 SUBRAMANI 60 M               8.6 7.9 2,16,000 
11 NATARAJ 55 M   p           6.7 6.1 2,87,000 
12 NAGARAJ 60 M               7.5 7.2 1,78,000 
13 LEELAVATHI 67 F   p p   p     8.1 7.4 2,09,000 
14 KUPPAN 68 M         p     7.8 7.5 3,90,000 
15 KUPPUSAMY 62 M     p   p     9 8.7 4,90,000 
16 GOVINDRAJ 65 M     p         7.1 6 1,29,000 
17 VIGNESHWARAN 68 M             p 8.8 7.3 1,67,000 
18 SWAMINATHAN 75 M   p p p       8.5 7.6 2,78,000 
19 LAKSHMI 77 F p             6.7 6.4 1,90,000 
20 VISWANATHAN 84 M p             5.9 6.4 2,90,000 
MASTER CHART - CONTROLS 
21 MUTHULAKSHMI 32 F   p p     p   8.1 7.3 1,78,000 
22 DURAISAMY 36 M       p       7.3 6.9 1,90,000 
23 SARAVANAN 45 M     p p       9 7.9 3,90,000 
24 DHANALAKSHMI 48 F             p 5.9 6.9 4,89,000 
25 SIVAKUMAR 56 M     p p       8.4 8.1 5,18,000 
26 TAMILSELVAN 53 M p   p p       6.7 6.4 2,01,000 
27 RAJAMMAL 55 F   p p         7.5 7.1 4,90,000 
28 RANGAN 52 M p   p   p     8.4 7 1,89,000 
29 KANAGARAJ 56 M     p         8.5 8.2 1,90,000 
30 MUTHUKUMAR 51 M               6.3 5.9 5,08,000 
31 MAYILSAMY 57 M   p           7.6 7.1 2,90,000 
32 KARTHIKEYAN 64 M       p p     8.6 8.2 2,90,000 
33 RAVEENDRAN 66 M p       p     6.5 5.9 4,89,000 
34 PALANIYAMMAL 67 F   p p         8.5 7.8 4,38,000 
35 RAVI 61 M     p         6 5.8 1,45,000 
36 VENKATACHALAM 66 M     p         7.7 7.1 3,90,000 
37 SHANTHI 70 F               8.7 8 4,90,000 
38 SUBBULAKSHMI 72 F p         p   8.6 8.1 5,00,000 
39 SHANMUGAM 79 M       p       8.2 8.2 1,98,000 
40 NAGESH 34 M   p p   p     7.2 6.6 1,96,000 
41 STALIN 38 M p             7.5 6.9 2,90,000 
42 ANGAPPAN 45 M   p p p       8.7 7.9 4,89,000 
43 KANNAMAL 50 F               6.5 6.7 3,90,000 
44 KUMARAN 55 M     p p       8 7.9 4,00,000 
45 ANGAMUTHU 52 M p p p   p     7.7 7.3 3,08,000 
46 SAVITHRI 58 F p   p         8.1 7.9 4,09,000 
47 SIVAN 52 M p   p   p     8.5 8.1 3,89,000 
48 RAJESH 58 M     p         6.1 5.8 4,08,000 
49 SELVAN 52 M               7.5 6.9 5,00,000 
50 FRANCIS 58 M p p           8.5 8.1 3,45,000 
51 RAMKUMAR 64 M p     p       8.5 8.2 1,35,000 
52 CHANDRASEKAR 69 M   p   p       6.7 6 1,79,000 
53 MANOKARAN 65 M p       p p   8.5 6 1,32,000 
54 PRABHAHARAN 61 M   p p         8.5 8.1 4,09,000 
55 ARUMUGAM 67 M   p p         7.5 8 2,09,000 
56 RAMANI 75 F     p         9 8 3,90,000 
57 THANGARAJ 76 M   p p p       7.1 6.7 2,99,000 
58 SITHALAKSHMI 78 F               8.3 8 4,00,000 
59 ANBUSELVI 37 F   p           7.3 6.7 2,88,000 
60 SELVI 42 F   p p         8.2 7.7 1,67,000 
61 FATHIMA 46 F p   p         8.3 8.2 2,67,000 
62 SHEKAR 45 M   p p p p     8.5 7.9 3,09,000 
63 VISWAMBHARAN 52 M   p p p p     7.3 7 4,78,000 
64 PERIYASAMY 52 M p p p p       8.3 7.8 1,90,000 
65 MARIYAPPAN 59 M p   p p p     8.3 8 2,38,000 
66 RAMESH 55 M p   p   p     7.2 6.7 4,00,000 
67 KARIYAN 58 M   p       p   7.7 6.4 2,05,000 
68 MURUGAN 55 M               8.3 7.9 3,98,000 
69 KARUPPUSAMY 59 M   p           8.5 8.1 1,56,000 
70 SELVARAJ 66 M p p   p       7.5 7.3 2,78,000 
71 SIVASHANKAR 68 M p     p p     7.5 7.1 2,88,000 
72 KRISHNA 64 M   p     p     8.2 6.2 4,99,000 
73 SURESH 63 M     p         8.3 7.5 4,90,000 
74 SATHEESH 68 M   p p     p   8 7.6 1,88,000 
75 CHITRA 77 F     p         8.2 7.6 1,97,000 
76 PANDISWARI 77 F               7 6.2 3,09,000 
77 VELDURAI 80 M         p     7 6.6 4,80,000 
78 KANDASAMY 39 M   p p p   p   7.1 6.8 3,90,000 
79 RAMALAKSHMI 43 F   p p         8.3 7.6 3,88,000 
80 JAYA 48 F   p           8.5 8 1,90,000 
81 BHASKAR 46 M     p p p     8.5 7.7 3,09,000 
82 SUDALAIMANI 53 M   p p   p     7.7 6.6 1,98,000 
83 ABRAHAM 52 M p   p   p     8.5 8 1,00,000 
84 KANNAN 55 M p   p p       7 6.6 2,09,000 
85 SELVARAJ 53 M     p   p     7.5 7.3 1,98,000 
86 MARIMUTHU 58 M               7.5 6.8 1,00,000 
87 MURUGESH 54 M               8.5 8.9 3,04,000 
88 DEVAKI 59 F p             5.9 6.2 2,22,000 
89 GOWTHAM 66 M p       p     8.5 8.3 1,30,000 
90 RAJASEKARAN 68 M         p p   8.1 7.4 2,90,000 
91 SUDHA 63 F     p         8.3 8 4,00,000 
92 KARUNAN 62 M     p         9 8 1,90,000 
93 DHARMAN 67 M   p p         9 7.9 2,99,000 
94 RUKMINI 71 F p       p     9 8.1 4,09,000 
95 SAKUNTHALA 78 F p             7.5 7 4,87,000 
96 SAVITHRI 82 F     p         6.2 5.8 1,09,000 
97 MUNIYANDI 29 M               7.5 6.9 2,07,000 
98 DINESH 26 M               7.7 7.1 3,09,000 
99 MURUGANANTHAN 23 M         p     7.6 7 1,40,000 
100 VELUSAMY 27 M p             8 7.2 3,50,000 
 KEY TO MASTER CHART 
 
p Presence of risk factors 
age Age in years 
M male 
F female 
DM Diabetes mellitus 
HTN hypertension 
CAD Coronary artery disease 
PLT Platelet count 
MPV Mean platelet volume 
D Dyslipidemia 
S Smoking 
A Alcoholism 
 
 
 
 
